An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Tumors or cancer of the LUNG.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the LIVER.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
A malignant epithelial tumor with a glandular organization.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A cell line derived from cultured tumor cells.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the human BREAST.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the NASOPHARYNX.
DNA present in neoplastic tissue.
Tumors or cancer of the ESOPHAGUS.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors or cancer of the URINARY BLADDER.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the BRONCHI.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Antibodies produced by a single clone of cells.
Tumors or cancer of the SKIN.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Tumors or cancer of the MOUTH.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the STOMACH.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Tumors or cancer of the COLON.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Transplantation between animals of different species.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the UTERINE CERVIX.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Elements of limited time intervals, contributing to particular results or situations.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the gallbladder.
RNA present in neoplastic tissue.
A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.
Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behavior of cells. Gastrin- releasing peptide (GRP); GRP 18-27 (neuromedin C), and neuromedin B are endogenous ligands of bombesin receptors in mammals.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Established cell cultures that have the potential to propagate indefinitely.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Tumors or cancer of the TONGUE.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Neoplasms composed of more than one type of neoplastic tissue.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)
Tumors or cancer of the SALIVARY GLANDS.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Biochemical identification of mutational changes in a nucleotide sequence.
The epithelial lining of the URINARY TRACT.
A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.
Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Tumors or cancer of the RECTUM.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
An organoplatinum compound that possesses antineoplastic activity.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
A type II keratin found associated with KERATIN-16 or KERATIN-17 in rapidly proliferating squamous epithelial tissue. Mutations in gene for keratin-6A and keratin-6B have been associated with PACHYONYCHIA CONGENITA, TYPE 1 and PACHYONYCHIA CONGENITA, TYPE 2 respectively.
Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Tumors or cancer located in bone tissue or specific BONES.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)
Cells with the capacity to take up and decarboxylate the amine precursors DIHYDROXYPHENYLALANINE or 5-HYDROXYTRYPTOPHAN. This is a property of endocrine cells of neural and non-neural origin. APUDOMA is a general term collectively applied to tumors associated with APUD cells.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Metastases in which the tissue of origin is unknown.
Surgical removal of the thyroid gland. (Dorland, 28th ed)
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (1/2496)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. (2/2496)

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. (3/2496)

The EPH family is the largest subfamily of receptor protein tyrosine kinases, consisting of the EPHA and EPHB subgroups. Ephrin-B1, ephrin-B2, and ephrin-B3 are ligands of the EPHB subgroup and are encoded by the EFNB1, EFNB2, and EFNB3 genes, respectively. We have shown previously that EPHB2 transcripts are expressed in six small cell lung carcinoma (SCLC) cell lines. In this study, we examined the expression of EPHB1, EPHB2, EPHB3, EPHB4, and EPHB6 in 4 SCLC tumor specimens and 14 cell lines including 3 cell lines derived from these tumor specimens. To investigate whether potential autocrine loops of EPHB receptors and ephrin-B ligands exist in SCLC, the expression of EFNB1, EFNB2, and EFNB3 was also examined. Our data show that transcripts encoding multiple members of the EPHB subgroup and the ephrin-B subgroup are coexpressed in SCLC cell lines and tumors. These results suggest that the EPHB subgroup receptor kinases may modulate the biological behavior of SCLC through autocrine and/or juxtacrine activation by ephrin-B ligands that are expressed in the same or neighboring cells.  (+info)

Combined modality therapy of lung cancer. (4/2496)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. (5/2496)

We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1-5 at 4-week intervals. Dose was escalated from 2 mg m(-2) day(-1) to 20 mg m(-2) day(-1) in 20 patients. Drug pharmacokinetics was analysed with high performance liquid chromatography with UV-detection. Plasma collected during drug administration was tested in vitro for growth inhibition of a teniposide-resistant small-cell lung cancer (SCLC) cell line. The predominant toxicities were elevated liver transaminases (maximum common toxicity criteria (CTC) grade 4) and serum creatinine (maximum CTC grade 2). These showed only a limited increase with increasing doses, often recovered during drug administration and were fully reversible. Duration of elevated alanine-amino transferase (ALT) was dose-limiting in one patient at 20 mg m(-2). Other frequent toxicities were grade 1-2 nausea/vomiting, fever and mild fatigue. Mean fostriecin plasma half-life was 0.36 h (initial; 95% CI, 0-0.76 h) and 1.51 h (terminal; 95% CI, 0.41-2.61 h). A metabolite, most probably dephosphorylated fostriecin, was detected in plasma and urine. No tumour responses were observed, but the plasma concentrations reached in the patients were insufficient to induce significant growth inhibition in vitro. The maximum tolerated dose (MTD) has not been reached, because drug supply was stopped at the 20 mg m(-2) dose level. However, further escalation seems possible and is warranted to achieve potentially effective drug levels. Fostriecin has a short plasma half-life and longer duration of infusion should be considered.  (+info)

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. (6/2496)

A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m(-2) and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m(-2), and the dose was escalated by an increase of 10 mg m(-2). The maximally tolerated dose of CPT-11 was determined as 60 mg m(-2) because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively.  (+info)

Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. (7/2496)

Patients with stiff man syndrome and breast cancer develop anti-amphiphysin I antibodies that primarily recognise the C terminus of the protein. Anti-amphiphysin I antibodies have also been identified in a few patients with paraneoplastic neurological disorders (PND) and small cell lung cancer (SCLC). The frequency of anti-amphiphysin I antibodies in patients with SCLC and PND was analysed and the epitope specificity of these antibodies was characterised. Anti-amphiphysin I antibodies were evaluated by immunohistochemistry on human and rat cerebellum and immunoblots of rat brain homogenates. Serum samples included 134 patients with PND and anti-Hu antibodies (83% had SCLC), 44 with SCLC and PND without anti-Hu-antibodies, 63 with PND and either Yo, Ri, or Tr antibodies, 146 with SCLC without PND, and 104 with non-PND. Positive serum samples were confirmed with immunoblots of recombinant human amphiphysin I and immunoreacted with five overlapping peptide fragments covering the full length of the molecule. Serum samples positive for anti-amphiphysin I antibodies included those from seven (2.9%) patients with PND and two (1.4%) with SCLC without PND. Six of the seven anti-amphiphysin I antibody positive patients with PND had SCLC (three with Hu-antibodies), and one had anti-Hu-antibodies but no detectable tumour. The PND included encephalomyelitis/sensory neuropathy (five patients), cerebellar degeneration (one), and opsoclonus (one). All anti-amphiphysin I antibodies reacted with the C terminus of amphiphysin I, but seven also recognised other fragments of the molecule. In conclusion, anti-amphiphysin I antibodies are present at low frequency in patients with SCLC irrespective of the presence of an associated PND. All anti-amphiphysin I antibody positive serum samples have in common reactivity with the C terminus of the protein.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (8/2496)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid progression and poor prognosis. We report a case of primary SCC of the breast that was diagnosed through pathologic and immuno
Small cell carcinomas (SCC) commonly arise in the respiratory tract; however, it is not uncommon for these cells to arise in nonpulmonary sites, as extrapulmonary small cell carcinoma (EPSCC). Small cell carcinoma is a distinct clinical and pathologic entity that arises from cells of the amine precursor uptake and decarboxylation (APUD) system.
Small cell carcinomas (SCC) commonly arise in the respiratory tract; however, it is not uncommon for these cells to arise in nonpulmonary sites, as extrapulmonary small cell carcinoma (EPSCC). Small cell carcinoma is a distinct clinical and pathologic entity that arises from cells of the amine precursor uptake and decarboxylation (APUD) system.
TY - JOUR. T1 - Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells. AU - Niiya, Masami. AU - Niiya, Kenji. AU - Shibakura, Misako. AU - Asaumi, Noboru. AU - Yoshida, Chikamasa. AU - Tanimoto, Mitsune. PY - 2006/3. Y1 - 2006/3. N2 - We previously demonstrated the doxorubicin-induced expression of urokinase-type plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α in human RCK8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Amurubicin hydrochloride (AMR), a novel derivative drug of doxorubicin, was recently introduced to clinical practice for treatment of lung cancer in Japan. Therefore, we investigated the effects of AMR on the expression of uPA and chemokines in NCI-H69 cells. AMR and its active form, amurubicinol hydrochloride (AMROH), both induced the expression of uPA, IL-8 and MCP-1 in H69 cells in a dose-dependent ...
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...
Purpose and methods: To develop a clinically useful approach to circumvent P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in MDR human small-cell lung cancer (SCLC), we examined the ability of a novel quinoline compound, MS-209, to reverse MDR by inhibition of P-gp function in combination with other MDR-reversing drugs using a cytotoxicity assay. Results: We established MDR human SCLC cells by culture in medium with gradually increasing concentrations of adriamycin (ADM). Compared with the parental human SCLC cells, SBC-3, the MDR variant SBC-3 cells obtained (SBC-3/ADM) were highly resistant to various chemotherapeutic agents due to P-gp expression. MS-209 reversed the resistance to ADM and vincristine (VCR) of SBC-3/ADM and H69/VP cells in a dose-dependent manner. Moreover, MS-209 in combination with cyclosporin A (CsA) or verapamil (VER) synergistically enhanced the antitumor effects of ADM and VCR on SBC-3/ADM cells. MS-209 restored ADM incorporation and this effect was enhanced by CsA
Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours.
TY - JOUR. T1 - F-18-FDG-PET/CT imaging of small cell carcinoma of the colon. AU - Jones, Katie. AU - Subramaniam, Rathan M.. AU - Durnick, David K.. AU - Peller, Patrick J.. PY - 2008/9/1. Y1 - 2008/9/1. N2 - Small cell carcinoma of the colon is a rare entity, comprising only 1.5% of all colon cancers. It is an aggressive neoplasm with rapid local progression and early metastasis. We present a case report of F-18 FDG PET/CT features of small cell carcinoma arising in the ascending colon of an 86-year-old woman who presented with anemia and melena. FDG PET/CT demonstrated a small, intense focus of FDG hypermetabolism in the cecum. Extrapulmonary small cell carcinoma, described in the salivary glands, pharynx, esophagus, stomach, small bowel, colon, rectum, gallbladder, uterus, kidney, and skin, has a poor prognosis when involving the gastrointestinal tract.. AB - Small cell carcinoma of the colon is a rare entity, comprising only 1.5% of all colon cancers. It is an aggressive neoplasm with rapid ...
This survey study compares use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer before and after the publication of a
TY - JOUR. T1 - Expression of the c-myb Oncogene in Human Small Cell Lung Carcinoma. AU - Griffin, Constance A.. AU - Baylin, Stephen B.. N1 - Copyright: Copyright 2016 Elsevier B.V., All rights reserved.. PY - 1985/1/1. Y1 - 1985/1/1. N2 - We have found that the oncogene c-myb is differentially expressed in human lung cancer cell lines and that myb-homolo-gous RNA can be detected only in small cell lung cancer (SCLC) cell lines. Polyadenylic acid-RNA from 13 established cell lines was examined by Northern blotting for its ability to hybridize to a radiolabeled v-myb probe. A 3.5-kilobase RNA transcript homologous to v-myb is present in four of four lines of classic SCLC and in three of four SCLC variant lines but not in five of five non-small cell lung cancer lines tested. This transcript is the same size as that found in the immature myeloid cell lines KG1, but the amount of RNA is only about 10% of that in the KG1 line. A second transcript hybridizing to v-myb, 2.4 kilobases in size, is also ...
RATIONALE: The general results of combining irinotecan and platin-based chemotherapies have been very encouraging. As the toxicity profile associated with carboplatin is preferable over cisplatin it is our expectation that patients and physicians would prefer to use this combination if it is equally or more efficacious. To date there has been no agreement regarding the optimal combination of these agents. Based on the trials described in the protocol and our experience with carboplatin/irinotecan in the treatment of non-small cell lung cancer the present trial will utilize a 21-day cycle of irinotecan 50 mg/m2 given on days 1 and 8 and carboplatin AUC 5 (based on the Calvert formula) on day 1.. PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin works as first-line therapy in treating patients with extensive-stage small cell lung cancer. ...
AstraZenecas Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.. SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.1,2. The approval by the European Commission was based on positive results from the Phase III CASPIAN trial showing Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit for the 1st-line treatment of patients with ES-SCLC. It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2020.. Luis Paz-Ares MD, Ph.D., Chair, Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain and principal investigator in the Phase III ...
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.. PURPOSE: This phase II trial is studying how well giving cisplatin, etoposide, and cyclophosphamide together works in treating patients with extensive-stage small cell lung cancer. ...
Among patients with extensive-stage small cell lung cancer, several groups were found to receive chemotherapy less often compared with White patients. They included Black, older and uninsured patients as well as those with nonprivate health insurance.
Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cance
BioAssay record AID 81529 submitted by ChEMBL: Cytotoxicity against NCI tumor panel, HOP-92 non small-cell lung cancer cell line.
This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC) that may be associated with timing of thoracic radiotherapy (TRT). ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy received prior to TRT, n = 65) or late-TRT (LRT; |3 cycles, n = 122). To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRRFS) were assessed and compared. Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS, and LRRFS were significantly longer in the TRT group than the non-TRT group (P | 0.001, all). However, between the
This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC) that may be associated with timing of thoracic radiotherapy (TRT). ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy received prior to TRT, n = 65) or late-TRT (LRT; |3 cycles, n = 122). To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRRFS) were assessed and compared. Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS, and LRRFS were significantly longer in the TRT group than the non-TRT group (P | 0.001, all). However, between the
TY - JOUR. T1 - Limited-stage small-cell lung cancer. T2 - Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. AU - Liengswangwong, V.. AU - Bonner, J. A.. AU - Shaw, E. G.. AU - Foote, R. L.. AU - Frytak, S.. AU - Eagan, R. T.. AU - Jett, J. R.. AU - Richardson, R. L.. AU - Creagan, E. T.. AU - Su, J. Q.. PY - 1994/3. Y1 - 1994/3. N2 - Purpose: This analysis was performed to determine the most appropriate volume that should be encompassed by thoracic radiation treatments (TRTs) for patients with limited-stage small-cell lung cancer (LSSCLC) who have responded to initial chemotherapy. Patients and Methods: A retrospective review of all patients (N = 67) with LSSCLC who were not entered onto a research protocol and were treated at our institution between the years of 1982 and 1990 was performed. Fifty-nine of 67 patients had adequate information regarding the size of the tumor before the start of chemotherapy (computed tomographic [CT] scan of chest or chest ...
For the second time this month, the FDA has given an approval to Genentechs PD-L1 inhibitor, Tecentriq.. On March 18, 2019, the FDA awarded the immunotherapy agent, Tecentriq (atezolizumab; Genentech), in combination with chemotherapy (carboplatin and etoposide), approval for the first-line treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC).. As evidence of the rapidity with which the immunotherapy field is gaining ground in cancer treatment, this new approval comes only 10 days after the drug received an accelerated approval (in combination with nab-paclitaxel) for the treatment of triple-negative breast cancer. Not only is this the second approval for atezolizumab in close succession to the first, but it is the first novel treatment in 2 decades for ES-SCLC, an aggressive and deadly malignancy.. This latest approval was based on data from the phase 3 IMpower133 trial, which was the first study to show that initial treatment with the immunotherapy-based combination ...
TY - CHAP. T1 - Bombesin stimulates growth of human small cell lung carcinoma in vivo. AU - Alexander, R. W.. AU - Upp, J. R.. AU - Poston, G. J.. AU - Gupta, V.. AU - Townsend, Courtney. AU - Thompson, J. C.. PY - 1987. Y1 - 1987. UR - http://www.scopus.com/inward/record.url?scp=0023610349&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023610349&partnerID=8YFLogxK. M3 - Chapter. AN - SCOPUS:0023610349. VL - 38. SP - 450. EP - 452. BT - Surgical Forum. ER - ...
On March 27, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (SCLC).. CASPIAN Trial. Efficacy of this combination in patients with previously untreated extensive-stage SCLC was investigated in CASPIAN, a randomized, multicenter, active-controlled, open-label phase III trial. The evaluation was based on the comparison of patients randomly assigned to durvalumab plus chemotherapy vs chemotherapy alone. The major efficacy outcome measure was overall survival; additional efficacy outcome measures were investigator-assessed progression-free survival and objective response rate per Response Evaluation Criteria in Solid Tumors, version 1.1.. Median overall survival was 13.0 months (95% confidence interval [CI] = 11.5-14.8) in the durvalumab-plus-chemotherapy arm vs 10.3 months (95% CI = 9.3-11.2) in the chemotherapy-alone arm (hazard ...
The Food and Drug Administration (FDA) has approved Zepzelca (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) whose disease progressed on or after receiving platinum-based chemotherapy.
Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database Rui Zhang,* Ping Li,* Qin Li, Yunfeng Qiao, Tangpeng Xu, Peng Ruan, Qibin Song, Zhenming Fu Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China *These authors contributed equally to this work Background: The survival advantage of radiotherapy for patients with extensive-disease small-cell lung cancer (ED-SCLC) has not been adequately evaluated.Methods: We analyzed stage IV SCLC patients enrolled from the Surveillance, Epidemiology, and End Results (SEER) registry through January 2010 and December 2012. Propensity score analysis with 1:1 matching was performed to ensure well-balanced characteristics of all comparison groups. Kaplan–Meier and Cox proportional hazardous model were used to evaluate the overall survival (OS), cancer-specific survival (CSS), and corresponding 95% CI.Results: Overall,
Cell lines derived from human small cell carcinoma of the lung express high levels of a surface polypeptide termed the cluster-w4 antigen, which was previously identified as a potential target for toxin-based immunotherapy of lung cancer. We have cloned a complementary DNA encoding the cluster-w4 antigen from COS-1 fibroblasts transfected with a SW2 small cell carcinoma library, by panning with a mixture of the cluster-w4-specific monoclonal antibodies SWA11, SWA21, and SWA22. The sequence of the cluster-w4 complementary DNA encodes an unusually short (80-amino acid) protein identical to that recently reported for the leukocyte activation molecule CD24 except for a single valine-alanine substitution due to a single-base polymorphism within the region of the gene coding for the extracellular domain. Biochemical analyses of the cloned cluster-w4 antigen confirmed both the presence of the phosphatidylinositol tail and the extensive glycosylation reported for the CD24 molecule. Furthermore, the cloned
BACKGROUND: Small cell anaplastic carcinoma most commonly presents as a lesion in the central portion of the lung but occasionally is found in peripheral locations. Only seven cases originating in the breast have been described. To our knowledge, the preoperative diagnosis of this entity by fine needle aspiration has not been previously reported in the cytologic literature. CASE: A 67-year-old female presented with a 4 x 3-cm, rapidly growing mass in the left breast. On fine needle aspiration (FNA) the tumor was soft to the needle and yielded a highly cellular aspirate. CONCLUSION: In this case the morphologic interpretation of FNA, combined with the immunocytochemical demonstration of neuron-specific enolase in tumor cells, was extremely helpful in establishing the nature of the breast tumor.
TY - JOUR. T1 - Induction of hydrogen peroxide production and bax expression by caspase- 3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. AU - Simizu, Siro. AU - Umezawa, Kazuo. AU - Takada, Minoru. AU - Arber, Nadir. AU - Imoto, Masaya. PY - 1998/1/10. Y1 - 1998/1/10. N2 - In our previous studies (S. Simizu, et al., 1996, Cancer Res. 56, 4978- 4982), we reported that apoptosis of human small cell lung carcinoma (SCLC) cells induced by protein tyrosine kinase inhibitors, such as erbstatin and herbimycin A, was mediated by H2O2 via a newly synthesized protein(s). In the present study, we demonstrated that induction of apoptosis by erbstatin resulted in activation of caspase-3(like) proteases, which are interleukin- 1β-converting enzyme family proteases (caspases) and that inhibition of these protease activities reduced the extent of cell death and H2O2 generation. We also demonstrated that expression of apoptotic protein Bax was induced ...
SCLC accounts for about 15% of all lung cancers, and it is strongly associated with tobacco use. SCLC is an aggressive cancer type, with a 5-year overall survival rate of about 6% to 7%. Although a number of combinations have been studied, until the recent advent of immune checkpoint inhibitors, standard first-line therapy for extensive-stage SCLC had remained etoposide/platinum for the preceding 30 years, Dr. Rudin noted. Although patients respond to etoposide/platinum, the median overall survival on this regimen is less than 1 year.. Pembrolizumab is currently U.S. Food and Drug Administration-approved for use as third-line or later therapy for metastatic SCLC. This study sought to explore its use in the first-line setting for SCLC.. Study Details. KEYNOTE-604 was conducted at 133 sites in 18 countries and randomly assigned 453 patients with previously untreated disease in a 1:1 ratio to pembrolizumab/etoposide/platinum or placebo/etoposide/platinum. Pembrolizumab was given as 200 mg once ...
Lung cancer is the most common cancer and also the leading cause of cancer-related death worldwide among both men and women. Small cell lung cancer (SCLC) accounts for 15% of all cases. It is the most aggressive one in its clinical behavior with a 5-year overall survival as low as 5%. Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase which regulates integrin and growth factor signaling pathways involved in cell proliferation, survival, migration, and invasion. FAK is overexpressed and/or activated in many cancers including SCLC. We hypothesized that FAK may represent a good target for therapeutic interventions in SCLC and tested the changes of cell phenotype induced by a FAK inhibitor (PF-228). ...
Currently, small-cell lung cancer accounts for about 15 percent of lung cancer diagnoses in the United States. Patients with the disease will initially respond to chemotherapy, but almost all will have disease recurrence within a couple of months, according to Lauren A. Byers, M.D., assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.. Unlike non-small cell lung cancer [NSCLC], where there have been new targeted drugs developed in the last ten years, the only currently approved treatments for small-cell lung cancer are cytotoxic chemotherapies, Byers said. Because most targeted therapies directly act on proteins, identifying if certain proteins are overexpressed in small-cell lung cancer could have therapeutic applications.. In order to identify molecular differences between NSCLC and the more aggressive small-cell lung cancer, Byers and colleagues used tools called reverse phase protein arrays. These allow the ...
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer._______In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backboneAstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to a hazard ratio of 0.73), with median OS of 13.0 months for
Chemicals. ABT-737 ((R)-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4′-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitro-benzenesulfonamide) was synthesized at Abbott Laboratories (Abbott Park, IL). Carboplatin and etoposide were purchased from Sigma (St. Louis, MO).. Cell culture. The SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 (Invitrogen Corp., Grand Island, NY) supplemented with 10% fetal bovine serum (Invitrogen), 1% sodium pyruvate, 25 mmol/L HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin (Sigma). All cell lines were maintained in a humidified chamber at 37°C containing 5% CO2.. The ABT-737-resistant H146 cells were derived from H146 cells by initially adding 40 nmol/L ABT-737 to their culture medium and thereafter doubling the concentration over a period of several ...
1. Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI. et al. Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. J Thorac Oncol. 2015;10:1213-20 2. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e400S-e19S 3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355-67 4. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A. et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-44 5. Buchholz E, Manegold C, Pilz L, Thatcher N, Drings P. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung ...
TY - JOUR. T1 - Delayed leuko-encephalopathy in survivors with small cell lung cancer. AU - So, N. K.. AU - ONeill, B. P.. AU - Frytak, S.. AU - Eagan, R. T.. AU - Earnest, F.. AU - Lee, R. E.. PY - 1987/7. Y1 - 1987/7. N2 - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case this was accompanied by CT and/or MRI evidence of changes in the peri-ventricular white matter. These patients are long-term survivors (41 to 69 months) and do not have CNS metastases.. AB - Six patients with small cell lung cancer developed a. slowly progressive neurologic syndrome characterized by apathy, abulia, memory loss, gait ataxia, and corticospinal tract signs 26 to 50 months (mean, 35.2 months) after prophylactic cranial irradiation and systemic chemotherapy. In each case ...
Lung cancer is a common malignant tumor including Small Cell Lung Cancer (SCLC) with 10 - 15 % and Non-Small Cell Lung Cancer (NSCLC) with 70 - 80%. Currently, there are several approaches to be used to treat lung cancer including surgery, chemotherapy, radiation therapy and molecular therapy/immunotherapy, Metastatic SCLC, metastatic mixed type of lung cancer and unclassified lung cancer are still difficult to be cured because this kind of lung cancer is easy to be widely disseminated. For example, if a patient has several metastatic SCLC, the patient will reveal poor outcome. In order to resolve the poor prognosis with recurrent and metastatic SCLC, here we reported a pathway-based approaches for analysis of Genome-Wide Association Studies (GWAS) to screen drugs, hence we used the drugs to treat a patient suffering from SCLC with multiple metastases. In the beginning, we harvested a pair of SCLC cells and normal cells from FFPE samples under laser capture microscopy to achieve the tumor cell DNA for
T-lymphokine-activated killer cell-originated protein kinase (TOPK) plays critical roles in cancer cell proliferation as well as maintenance of cancer stem cells (CSC). Small cell lung cancer (SCLC) has highly aggressive phenotype, reveals early spread to distant sites, and results in dismal prognos …
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop t
Description: Neuroendocrine xenograft model of human prostatic small cell carcinoma cancer. Provides a source to study the involvement of neuroendocrine cells in the progression of prostatic adenocarcinoma and can serve as a novel model for the testing of new therapeutic strategies for prostatic small cell carcinoma.. WISH-PC2: Taken from a patient diagnosed with T3N1M1 prostatic adenocarcinoma with a Gleason score of 8 (3 + 5). Obtained during a palliative transuretheral resection of the prostate. Independent of Androgen and does not secretes prostate-specific antigen.. WISH-PC14: Taken from a channel transurethral resection of the prostate of a late recurrent primary tumor, Gleason score 9 (4 + 5), after definitive radiation therapy. Androgen dependent and secretes prostate-specific antigen. WISH-PC23: Taken from prostatic adenocarcinoma harvested during palliative trans urethral resection of the prostate performed in a patient with local progression of adenocarcinoma of the prostate, Gleason ...
Small cell lung cancer information with its causes along with various signs and symptoms. The fluid in the lungs may be an indication of this cancer but this may not be a sure sign of the disease. Detailed description of small cell lung cancer different treatment methods also given.
Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer ...
Management of limited small cell lung cancer(SCLC). small cell lung cancer is very responsive to chemotherapy and radiotherapy. Most of the times it is disseminated. Surgery should only be done when chemotherapy has failed. Platinum compounds and etoposide combined with thoracic radiation is used. Prognosis and survival in small cell lung cancer; mosts of the times the patients present with a disseminated disease. If not treated, patients can survive for up to four months. when treated early, patients can live up to two years without the disease. About 5-10% of patients treated live up to five years.. Management of advanced small cell lung cancer(SCLC). The first line drugs in treatment of advanced small cell lung cancer is a combination of carboplastin or cisplatin combined with etoposide. Patients with small cell lung cancer have poor survival rates of ten months to two years in about 10% of the patients. ...
TY - JOUR. T1 - Limited value of CT brain scans in the staging of small cell lung cancer. AU - Johnson, D. H.. AU - Windham, W. W.. AU - Allen, J. H.. AU - Greco, F. A.. PY - 1982/1/1. Y1 - 1982/1/1. N2 - Computed tomography of the brain was performed as part of the initial staging evaluation of 84 patients with small cell lung cancer. Brain scans indicative of metastatic disease were obtained in 12 (14%) patients, two of whom had no neurologic signs or symptoms. One of these had no other extrathoracic disease. Brain scans without evidence of metastatic diseases were obtained in 72 patients, 58 (80.5%) of whom had no signs or symptoms suggestive of metastatic intracranial disease. In the 14 patients with neurologic symptoms but negative computed tomographic scans, other explanations than brain metastases were found. It was concluded that head scanning is a sensitive and accurate method of detecting central nervous system metastases in patients with small cell lung cancer. However, head computed ...
Get information, facts, and pictures about Small cell lung cancer at Encyclopedia.com. Make research projects and school reports about Small cell lung cancer easy with credible articles from our FREE, online encyclopedia and dictionary.
The identification of genes undergoing genetic or epigenetic alterations and contributing to the development of cancer is critical to our understanding of the molecular mechanisms of carcinogenesis. A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells
Background: Much research has confirmed the favorable effect of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) on extensive-stage small cell lung c
Clinical trial for sclc | small cell carcinoma | Small Cell Lung Cancer | Neuroendocrine carcinoma | small cell carcinoma of the lung | Merkel cell carcinoma | Neuroendocrine Carcinoma , Safety and Efficacy of XmAb18087 Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format. By default, clicking on the export buttons will result in a download of the allowed maximum amount of items. To select a subset of the search results, click Selective Export button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export. After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format. ...
TY - JOUR. T1 - Primary combined small cell carcinoma of larynx with lateralized histologic components and corresponding sidespecific neck nodal metastasis. T2 - Report of a unique case and review of literature. AU - Aggarwal, Gitika. AU - Jackson, Lana. AU - Sharma, Suash. PY - 2011/11/2. Y1 - 2011/11/2. N2 - Combined small cell carcinoma (neuroendocrine) of the larynx has been rarely reported in the literature, and included in the current WHO classification. We hereby report an unusual case of combined carcinoma of the larynx; composed mainly of small cell neuroendocrine carcinoma nearly confined to the right side (mainly involving supraglottis extending to glottis) with synchronous minor in-situ and invasive squamous cell carcinoma component located on the left side of larynx (mainly glottis). Interestingly, this side-specific distribution of tumor was recapitulated in its metastatic nodal spread; so that right cervical lymph nodes showed only metastatic small cell carcinoma and left cervical ...
TY - JOUR. T1 - NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. AU - Ikematsu, Yuki. AU - Tanaka, Kentaro. AU - Toyokawa, Goji. AU - Ijichi, Kayo. AU - Ando, Nobuhisa. AU - Yoneshima, Yasuto. AU - Iwama, Eiji. AU - Inoue, Hiroyuki. AU - Tagawa, Tetsuzo. AU - Nakanishi, Yoichi. AU - Okamoto, Isamu. N1 - Publisher Copyright: © 2020 Elsevier B.V. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 2020/8. Y1 - 2020/8. N2 - Introduction: Small cell lung cancer (SCLC) manifests high-grade neuroendocrine features, and the transcription factors ASCL1 and NEUROD1 play an important role in the survival and growth as well as contribute to the heterogeneity of SCLC cells. The relative abundance of ASCL1 and NEUROD1 mRNAs differs among human SCLC cell lines, but the expression pattern of the encoded proteins in clinical SCLC specimens and its relation to clinicopathologic characteristics of patients have been unclear. Materials and ...
We conducted a trial of adaptive radiotherapy (RT) for limited stage small cell lung cancer (LS-SCLC) to quantify the dosimetric advantages, toxicity, survival and failure patterns associated with this technique.
Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database.
0079]Both the NPR-A and NPR-C (i.e. clearance) receptors were present in these small-cell lung cancer cells. This knowledge helps to explain BNPs and CNPs lack of biologic effects in these cancer cells at their 1-μM concentrations. Atrial natriuretic peptide binds to both the NPR-A and C-receptors with a higher affinity than BNP or CNP. Binding to the NPR-A receptor is ANP,BNP,,CNP while binding to the NPR-C receptor is ANP,CNP,BNP. Binding of human BNP to the human NPRC receptor is an order of magnitude lower than ANP, indicating that an order of magnitude larger concentration of BNP is necessary to be present for BNP to have effects. In the present investigation the inventors have investigated BNP and CNP, which had no effects at 1 μM whereas the other peptide hormones did, at 10-fold and 100-fold higher concentrations. At 10-fold higher (i.e. 10 μM) concentrations of BNP and CNP, neither significantly decreased the number of human small-cell lung cancer cells. Anticancer effects were ...
Lung cancer is the major cancer killer in the Western world, with the small cell lung cancer (SCLC) representing around 15-20% of all lung cancers. Extensive disease small cell lung cancer (ED SCLC) is found in approximately two-thirds of all cases, composed of both metastatic (M1) and non-metastatic (but presumably with tumor burden too large for locoregional-only approach) variant. Standard treatment options involve chemotherapy (CHT) over the past several decades. Radiation therapy (RT) had mostly been used in palliation of locoregional and/or metastatic disease. In contrast to its established role in treating metastatic disease, thoracic RT (TRT) had never been established as important part of the treatment aspects in this setting. In the past two decades, thoracic oncologists have witnessed wide introduction of modern RT and CHT aspects in ED SCLC, which led to more frequent use of RT and rise in the number of clinical studies. Since the pivotal study of Jeremic et al., who were the first to show
BM is a well-known negative prognostic factor in SCLC and NSCLC patients, and a previous retrospective analysis of SCLC patients showed significantly shorter OS of patients with BM than among patients without BM [4.13 vs. 6.17 months, P=0.015 (11)]. In NSCLC patient cohorts, the incidence of SREs is also a known negative prognostic factor, with one year survival rates of 5.1 and 12.1% in a retrospective cohort study of lung cancer patients with and without SREs, respectively (12). However, this study showed no significant differences in OS between ES-SCLC patients with BM and metastasis in the brain, liver, adrenal glands and pleural cavities. Other studies suggest that liver metastases are the worst prognostic factor in patients with ES-SCLC (13,14), and that BM and brain metastases are similarly negative survival indicators. Specifically, one-year survival of SCLC patients with liver, brain and BM was 14.5, 25.1 and 23.9%, respectively (13), warranting consideration of BM as an important ...
TY - JOUR. T1 - Phase I study of topotecan and cisplatin in patients with small cell lung cancer. AU - Ichinose, Yukito. AU - Seto, Takashi. AU - Nishiwaki, Yutaka. AU - Kiura, Katsuyuki. AU - Sakai, Hiroshi. AU - Yokoyama, Akira. AU - Segawa, Yoshihiko. AU - Ando, Masahiro. AU - Watanabe, Koshiro. PY - 2011/2. Y1 - 2011/2. N2 - Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m2/day), and cisplatin at a fixed dose of 60 mg/m2, 3 weeks cycle. This study employed the following stages: cisplatin was given ...
The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at- http://www.absolutereports.com/opportunityanalyzer-small-cell-lung-cancer-sclc-opportunity-analysis-and-forecasts-to-2024-10112598. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor Yervoy will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.. The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment ...
By Scott Roberts TUESDAY, March 19, 2019 (HealthDay News) -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC).. The drug has been approved as a first-line treatment for the disease, to be used in combination with the chemotherapy drugs carboplatin and etoposide.. Tecentriq was evaluated in a clinical study involving 403 adults who had received no prior chemotherapy, the FDA said in a news release.. Average survival for those who took the Tecentriq combination was 12.3 months, compared to 10.3 months among those who took the chemotherapy drugs and a placebo.. The most common side effects among the Tecentriq group were fatigue, nausea, temporary baldness, constipation and loss of appetite.. The newly approved drug is produced by Genentech, based in South San Francisco.. More information. The FDA has more about this approval.. Copyright © 2019 HealthDay. All rights reserved. ...
TY - JOUR. T1 - Cisplatin-etoposide induced myocardial infarction in a patient with small cell carcinoma. AU - Katta, Srija. AU - Chauhan, Sheetal. AU - Singh, Ajit. AU - Shetty, Prasad N.. AU - Kareem, Hashir. AU - Devasia, Tom. PY - 2018/5/1. Y1 - 2018/5/1. N2 - Various drugs used to treat cancer cause hemodynamic/physiological changes in various organs of the body. Cardiotoxicity is one of the major side effects. Cardiotoxicity associated with chemotherapy can range from asymptomatic sub-clinical echocardiographic changes to life-threatening events like congestive heart failure or acute coronary syndrome. We present a case of cisplatin and etoposide-induced myocardial infarction (MI) during the second cycle of chemotherapy for bronchogenic carcinoma of the left lung (small cell carcinoma). The patient developed troponin positive NSTEMI and was managed conservatively. Here, the possible mechanism of action and the importance of cardiac screening while using cisplatin and etoposide are ...
Introduction Conventionally, palliative care services have been viewed as a terminal line of management when primary treatment is unsuccessful. Recent studies have shown that integration of palliative care medicine with medical oncology care substantially increases quality of life and survival duration in patients with non-small cell lung cancer1. This study was carried out in the Beaumont Hospital Cancer Centre highlighting the patterns of palliative care and medical oncology interventions in the management of patients with small cell lung cancer (SCLC).. Methods Information from patient records, intranetwork hospital databases, pathological reports, pharmaceutical entries and clinical notes of all patients diagnosed with SCLC through the Rapid Access Lung Cancer Clinic (RALCC) between 2008 to 2011 was compiled into a database.. Results Between 2008 to 2011, 58 patients presented to the RALCC and were diagnosed with small cell lung cancer. From this total amount, 50 patients were actively ...
TY - JOUR. T1 - Neurotensin may function as a regulatory peptide in small cell lung cancer. AU - Davis, Thomas P.. AU - Crowell, Susan. AU - McInturff, Brena. AU - Louis, Renee. AU - Gillespie, Terry. PY - 1991/1/1. Y1 - 1991/1/1. N2 - Neurotensin (NT) has been postulated to act as a modulatory agent in the central nervous system. Besides its presence in mammalian brain, NT is produced by small cell carcinoma of the lung (SCLC) and cell lines derived from these tumors. Receptors have also been characterized in some SCLC cell lines leading to the suggestion that NT could regulate the growth of SCLC in an autocrine fashion similar to bombesin/GRP. Previously, we had reported that a 10 nM dose of NT and NT(8-13), but not NT(1-8), elevated cytosolic Ca2+, indicating that SCLC NT receptors may use Ca2+ as a second messenger. Using intact SCLC cells we report that time-course incubations with NT lead to the formation of the amino-terminal fragment NT(1-8) and small amounts of the C-terminal fragment ...
TY - JOUR. T1 - Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. AU - Figoli, Franco. AU - Veronesi, Andrea. AU - Ardizzoni, Andrea. AU - Canobbio, Luciano. AU - Bruschi, Gioia. AU - Mazza, Francesco. AU - Zagonel, Vittorina. AU - Lo Re, Giovanni. AU - Rosso, Riccardo. AU - Monfardini, Silvio. PY - 1988. Y1 - 1988. N2 - Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7% complete responses (CR) and 9 (33% partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of ...
TY - JOUR. T1 - Similar outcome of elderly patients in Intergroup Trial 0096. T2 - Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. AU - Yuen, Alan R.. AU - Zou, Guangyong. AU - Turrisi, Andrew T.. AU - Sause, William. AU - Komaki, Ritsuko. AU - Wagner, Henry. AU - Aisner, Seena C.. AU - Livingston, Robert B.. AU - Blum, Ronald. AU - Johnson, David H.. PY - 2000/11/1. Y1 - 2000/11/1. N2 - BACKGROUND. Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS. In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m2, Day 1 and etoposide 120 mg/m2, Days 1-3 for 4 cycles and either once or twice ...
Ras. Ras is an oncogene that is altered in up to 30% of non small cell lung cancers (NSCLC).17 The ras protein is involved in transmitting signals through the cell that drive the cell into the division process. Learn more about Ras. Myc. The Myc family of oncogenes that are expressed abnormally in many types of cancer, including lung cancer. The myc protein acts as a transcription factor to regulate the expression of several genes. Learn more about transcription and transcription factors. Myc protein expression is altered in up to 80% of small cell lung cancers (SCLC).17Learn more about Myc. Rb. The retinoblastoma gene (Rb) is a tumor suppressor altered in up to 90% of small cell lung cancers (SCLC).17Learn more about tumor suppressors The Rb protein interacts with transcription factors to indirectly control cell division. Learn more about Rb. TP53. TP53 (or P53) is a tumor suppressor gene altered in up to 50% of non small cell lung cancers (NSCLC) and 80% of small cell lung cancers (SCLC).17 ...
Lim, G., J. Karaskova, et al. (2005). An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 42(4): 392-403. Coe, B. P., L. J. Henderson, et al. (2005). High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes Cancer 42(3): 308-13. Garnis, C., B. Coe, et al. (2004). Construction and optimization of chromosome arm-specific comparative genomic hybridization arrays for identifying genetic alterations in preinvasive lung cancers. Chest 125(5 Suppl): 104S-5S. Garnis, C., B. P. Coe, et al. (2004). Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas. Oncogene 23(14): 2582-6. de Leeuw, R. J., J. J. Davies, et al. (2004). Comprehensive whole genome array CGH ...
Cancer stem cells (CSCs) are considered as the origin of tumor relapse. Here, we investigated the effects of Fructus Viticis total flavonoids (FVTF) on the characteristics of lung cancer stem-like cells (LCSLCs) derived from human small cell lung cancer NCI-H446 cell line and its potential mechanism. Human small cell lung cancer NCI-H446 cell line was cultured in vitro. The CD133+ cells were sorted from NCI-H446 cell line by magnetic separation. The suspended culture with stem cell-conditioned medium was used to amplify CD133+ sphere-forming cells (SFCs). The stem cell characteristics of CD133+ SFCs were evaluated using cell self-renewal capacity by tumor sphere formation assay, migration and invasion capacity by Transwell assay, tumorigenicity by xenograft model in nude mouse and cancer stem cell markers expression levels by western blot. The effects of FVTF on the properties of LCSLCs were examined by tumorsphere formation assay and transwell chamber assay. The expression level of p-Akt was determined
Comoglio, P.M., 1988: Autocrine activation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinoma
Small cell carcinoma of the urinary bladder (SCCUB) is considered to be a tumor with a neuroendocrine phenotype characterised by aggressive behaviour and poor prognosis. Small cell carcinoma of the urinary bladder comprises 0.35 to 1% of all bladder cancers and is frequently observed in combination with other histological subtypes of carcinoma. Clinical presentation is characterized by advanced stage at diagnosis and rapidly progressive disease. In daily clinical practice there is no gold standard for the management of patients affected by this disease. Treatment of patients with limited disease combines neoadjuvant platinum-based chemotherapy followed by specific local treatment of the primary tumour. Cystectomy or radiotherapy should be proposed on an individual basis. In the metastatic setting, prognosis remains poor with a potential benefit from chemotherapy containing platinum compounds. Treatment of small cell carcinoma of the urinary bladder is based on evidence obtained from case reports ...
TY - JOUR. T1 - Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxoruhicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. AU - Ardizzoni, A.. AU - Pennucci, M. C.. AU - Danova, M.. AU - Viscoli, C.. AU - Mariani, G. L.. AU - Giorgi, G.. AU - Venturini, M.. AU - Mereu, C.. AU - Scolaro, T.. AU - Rosso, R.. PY - 1996. Y1 - 1996. N2 - A phase I study was designed to assess whether dose intensity of an accelerated cyclophosphamide- doxorubicin- etoposide (CDE) regimen plus granulocyte colony-stimulating factor (G-CSF) could be increased further, in an outpatient setting, by escalating the dose of each single drug of the regimen. Patients with previously untreated small-cell lung cancer (SCLC) received escalating doses of cyclophosphamide (C) 1100-1300 mg m-2 intravenously (i.v.) on day I, doxorubicin (D) 50-60 mg m-2 i.v. on day 1, etoposide (E) 110-130 mg m-2 i.v. ...
Object. Lung carcinoma is the leading cause of death from cancer. More than 50% of those with small cell lung cancer develop a brain metastasis. Corticosteroid agents, radiotherapy, and resection have been the mainstays of treatment. Nonetheless, median survival for patients with small cell lung carcinoma metastasis is approximately 4 to 5 months after cranial irradiation. In this study the authors examine the efficacy of gamma knife surgery for treating recurrent small cell lung carcinoma metastases to the brain following tumor growth in patients who have previously undergone radiation therapy, and they evaluate factors affecting survival.. Methods. A retrospective review of 27 patients (47 recurrent small cell lung cancer brain metastases) undergoing radiosurgery was performed. Clinical and radiographic data obtained during a 14-year treatment period were collected. Multivariate analysis was utilized to determine significant prognostic factors influencing survival.. The overall median survival ...
Lung cancer treatments can cause side effects. Side effects from lung cancer treatment are common, but just because a side effect is common does not mean that a patient will experience it. Before treatment begins for small cell lung cancer, patients should discuss with their healthcare team what side effects might be expected and how to prevent or ease them. Patients should also speak with their healthcare team if and when new side effects begin, as treating them early on is often more effective than trying to treat them once they have already become severe. Although most side effects go away when treatment is over, some can last a long time.. In addition to the side effects of lung cancer treatments, lung cancer itelf can result in a number of symptoms. For more information about the symptoms of lung cancer, see the Signs & Symptoms section.. Tips for managing specific symptoms and side effects related to treatment can be found in the For Supporters & Advocates section of the website, along ...
Currently, lung cancer is classified into two broad histological subgroups: non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The distinction between these two categories is important because the treatment options differ substantially. There are different chemotherapeutic regimens for SCLC and NSCLC, and the initial response to chemotherapy is much greater for patients with SCLC than for those with NSCLC [1,2]. Currently, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first-line treatment for a subset of EGFR-mutated NSCLC patients [3]. In many cases, however, acquired resistance emerges within a year [4]. Although the secondary T790M mutation has been well-described and reported in up to 60% of resistant samples [5], there have been several studies proposing histological transformation from NSCLC to SCLC as another mechanism of EGFR TKI resistance [2,5-12]. The possible explanation of this phenomenon can be the transformation of ...
Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control ...
Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control ...
Paraneoplastic syndrome is often associated with small cell lung cancer that has the potential to cause disability to a multitude of organ function.
Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we...
Small cell lung cancer survival rate depends on some factors. Usually, the survival rate is based on the stage. The higher the stage of the cancer is the l
TY - JOUR. T1 - Analysis of Protein Expression and Gene Mutation of c-kit in Colorectal Neuroendocrine Carcinomas. AU - Akintola-Ogunremi, Olaronke. AU - Pfeifer, John D.. AU - Tan, Benjamin R.. AU - Yan, Yan. AU - Zhu, Xiaopei. AU - Hart, John. AU - Goldblum, John R.. AU - Burgart, Lawrence. AU - Lauwers, Gregory Y.. AU - Montgomery, Elizabeth. AU - Lewin, David. AU - Washington, Kay. AU - Bronner, Mary. AU - Xiao, Shu Yuan. AU - Greenson, Joel K.. AU - Lamps, Laura. AU - Lazenby, Audrey. AU - Wang, Hanlin L.. PY - 2003/12. Y1 - 2003/12. N2 - Primary neuroendocrine carcinomas of the colon are rare but highly aggressive malignancies. The recent observations that c-kit protooncogene, a tyrosine kinase, is overexpressed in a subset of small cell lung cancer and that selective kinase inhibitors block the in vitro growth of small cell lung cancer cell lines prompted us to investigate the expression and mutation status of the c-kit gene in colorectal neuroendocrine carcinomas. Sixty-six cases of ...
Advanced small cell lung cancer (SCLC) has a dismal prognosis. Modulation of the camptothecin topotecan, approved for second-line therapy, may improve response. Our recent finding of synergistic enhancement of the cytotoxic activity of camptothecin (CPT) by cyclin-dependent kinase 4 inhibitors is extended here to a panel of camptothecin analogs comprising 10-hydroxy-CPT (HOCPT), topotecan (TPT; 9-[(dimethylamino)-methyl]-10-hydroxy-CPT), 9-amino-CPT (9AC), 9-nitrocamptothecin (rubitecan), SN38 (7-ethyl-10-hydroxycamptothecin) and 10-hydroxy-9-nitrocamptothecin (CPT109) in combination with PD0332991, CDK4I, roscovitine and olomoucine. SCLC cell lines employed are chemoresistant NCI-H417 and DMS153 and the chemosensitive SCLC26A line established at our institution. The CPT analogs exhibiting highest cytotoxicity towards the three SCLC lines tested were SN38 and 9AC, followed by rubitecan, HOCPT, TPT and CPT109. NCI-H417 and DMS153 revealed an approximately 25-fold and 7-fold higher resistance compared to
The relationship between tumor physiology and the pharmacokinetics of 2,2 difluorodeoxycytidine [gemcitabine (dFdC)] in ex vivo perfused human small cell lung cancer was examined. Two small cell lung cancer sublines, 54A and 54B, with known in vivo sensitivity to dFdC, were grown as tissue-isolated tumors in athymic mice and perfused ex vivo with or without 20-40 micrometer dFdC. Arteriovenous differences in gases, pH, and metabolites were determined before and during drug infusion. The geometric flow resistance (FR) of individual tumors was calculated, and dFdC and its inactive metabolite 2,2 difluorodeoxyuridine were determined by high-performance liquid chromatography of consecutive samples from the output line. Both tumors had prominent lactate production concurrent with a significant O2 consumption. The arteriovenous pH drop was approximately 0.3 in both tumor lines. Significant metabolic differences between 54A and 54B tumors were found that elucidated previously described differences ...
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Random
Previous data from our laboratory has indicated that there is a functional link between the β-adrenergic receptor signaling pathway and the G-protein inwardly rectifying potassium channel (GIRK1) in human breast cancer cell lines. We wanted to determine if GIRK channels were expressed in lung cancers and if a similar link exists in lung cancer. GIRK1-4 expression and levels were determined by reverse transcription polymerase chain reaction (RT-PCR) and real-time PCR. GIRK protein levels were determined by western blots and cell proliferation was determined by a 5-bromo-2-deoxyuridine (BrdU) assay. GIRK1 mRNA was expressed in three of six small cell lung cancer (SCLC) cell lines, and either GIRK2, 3 or 4 mRNA expression was detected in all six SCLC cell lines. Treatment of NCI-H69 with β2-adrenergic antagonist ICI 118,551 (100 μM) daily for seven days led to slight decreases of GIRK1 mRNA expression levels. Treatment of NCI-H69 with the β-adrenergic agonist isoproterenol (10 μM) decreased growth
Aim of the sudy was to investigate the epidemiological changes of patients with lung cancer over the years.. 721 lung cancer cases diagnosed between January 2000 and January 2013 years were included.The patient were categorized in three group according to thier diagnosis time as 2000-2005,2006-2010,and 2011-2013.. 79,2% of patients were male and mean age was 60,4±7,9 years.The percentage of squamous cell carcinoma (SCC),adenocarcinoma, other non small cell lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC) were 35.4%, 26.7%, 8.4%, and 29.5% respectively.The percentage of stage IIIB and IV of NSCLC were 49,3% and 29,1 respectively.Between 2000-2005 years, 90,6% of patients were male and mean age was 69,7±11,9 years.The percentage of SCC,adenocarcinoma,other NSCLC, and SCLC were 45,7%, 6,9%, 17,2%, and 30,2% respectively.The percentage of stage IIIB and IV of NSCLC were 45,9% and 41,8% respectively.Between 2006-2010 years, 80,72% of patients were male and mean age was 61,8±5,4 ...
In this study, we used proteomic and gene expression profiling to identify pathways dysregulated in SCLCs. We discovered higher expression of several E2F1-regulated proteins (e.g., EZH2, DNA repair, and apoptosis proteins) and PARP1, an E2F1 co-activator (21, 22). Conversely, our study revealed that EGFR, its associated RTKs (e.g., Her2, c-Met, Axl), and downstream targets in the PI3K/Akt/mTOR pathway and the RAS/Raf/MEK pathway were expressed at lower levels in SCLCs. Our analysis also detected known abnormalities in SCLCs, such as c-Kit and Bcl-2 overexpression and Rb loss.. Loss of the RB1 gene is a hallmark of SCLCs. Consistent with this, in our study, total and phospho-Rb protein expression was reduced or absent in SCLCs. Given that Rb is known to inhibit the transcription factor E2F1, this loss of Rb activity is a likely explanation for the observed increases in protein expression of E2F1 and E2F1 targets in SCLCs. To our knowledge, this study represents that first time several of these ...
SCLC tumors usually grow faster than non-small cell lung cancer (NSCLC) tumors, and are sometimes initially more responsive to chemotherapy.
Background Most individuals with small cell lung cancer (SCLC) or neuroblastoma (NB) already show clinically detectable metastases at diagnosis and have an extremely poor prognosis even when treated with combined modalities. tumor growth was also observed. In neuroblastoma allografted A/J mice (n?=?5) treated twice PF-3845 with intratumoral immunotoxin, significant tumor regression occurred in over 80% of the animals and their duration of tumor response was significantly prolonged. Conclusions Our study suggests that anti-HuD based immunotoxin therapy may prove to be an effective alternative treatment for patients with SCLC and NB. Background Both small cell lung cancer (SCLC) and neuroblastoma (NB) express high-levels of HuD protein. HuD is a 40 kD neuronal RNA-binding protein that is expressed in 100% of SCLC tumor cells and at least 50% of NB cells [1]. Most patients with SCLC or NB have disseminated disease at the time of diagnosis and the prognosis is usually poor despite aggressive ...
The results of a recently reported clinical study at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco demonstrate that thoracic radiation improves survival and reduces cancer recurrence when added to prophylactic cranial irradiation in patients with extended-stage small cell lung cancer.(1) Small-cell lung cancer (SCLC) is a fast-growing […]. ...
Non-small-cell lung carcinoma[edit]. Micrograph of squamous-cell carcinoma, a type of non-small-cell carcinoma, FNA specimen, ... are carcinomas.[12] The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC).[3] The ... For therapeutic purposes, two broad classes are distinguished: non-small-cell lung carcinoma and small-cell lung carcinoma.[66] ... Small-cell lung carcinoma (SCLC), non-small-cell lung carcinoma (NSCLC)[3]. ...
Micrograph of a small-cell carcinoma showing cells with nuclear moulding, minimal amount of cytoplasm and stippled chromatin. ... Micrograph showing the yolk sac component of a mixed germ cell tumour. H&E stain. ... these include leukemia and most forms of carcinoma in situ. Tumor is also not synonymous with cancer. While cancer is by ... a solid or fluid-filled cystic lesion that may or may not be formed by an abnormal growth of neoplastic cells) that appears ...
Pleural desmoplastic small round cell tumor (pleural DSRCT). *Pleural synovial sarcoma. *Pleural solitary fibrous tumor ( ... Pleural carcinomas *Pleural mucoepidermoid carcinoma. *Pleural pseudomesotheliomatous adenocarcinoma. See also[edit]. *Pleural ...
Small cell carcinoma, a common cause of ACTH secreted ectopically. *Congenital adrenal hyperplasia, diseases in the production ... ACTH acts by binding to cell surface ACTH receptors, which are located primarily on adrenocortical cells of the adrenal cortex ... ACTH also stimulates lipoprotein uptake into cortical cells. This increases the bioavailability of cholesterol in the cells of ... ACTH stimulates secretion of glucocorticoid steroid hormones from adrenal cortex cells, especially in the zona fasciculata of ...
July). „K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer 8 (1), 30-38. o, Kiadó: Cancer ... A nem-kissejtes (Non-small cell lung carcinoma) elváltozásokat egy csoportba sorolják, mivel kezelésük és kimenetelük hasonló. ... A kissejtes tüdőrák (Small cell carcinoma) egy kevésbé gyakori forma. A primer és secunder hörgőkből eredő elváltozás gyorsan ... 1977). „Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports 61 (3), 349-354. o. PMID 194691 ...
Small cell carcinoma is a very rare (1%[77]) type of prostate cancer that cannot be diagnosed using the PSA.[77][78] As of 2009 ... Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in ... "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340-1. PMC 1296316 . PMID 9227387.. ... LNCaP cells express androgen receptor (AR), but PC-3 and DU-145 cells express very little or no AR. AR, an androgen-activated ...
non-seminomatous germ cell tumors PEI cisplatin, etoposide, ifosfamide small-cell lung carcinoma ... B cell non-Hodgkin lymphoma FCM-R or R-FCM or R-FMC or FMC-R fludarabine, cyclophosphamide, mitoxantrone plus rituximab B cell ... B cell non-Hodgkin lymphoma R-ICE or ICE-R or RICE rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide high ... "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) ...
Većina tipova plućnih kancera su plućni karcinomi malih-ćelija (engl. small-cell lung carcinoma, SCLC). Najčešći simptomi su ... 1977). „Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports. 61 (3): 349-354. PMID 194691.. ... 2006). „K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer. Cancer Information Group. 8 (1): 30- ... 2006). „Small cell lung cancer". Annals of Oncology. 17 (Suppl. 2): 5-10. PMID 16608983. doi:10.1093/annonc/mdj910.. ...
Small cell carcinoma is a rare (1%) type that cannot be diagnosed using PSA. As of 2009[update] researchers were investigating ... LNCaP cells express AR, but PC-3 and DU-145 cells express very little or no AR. The proliferation of LNCaP cells is androgen- ... Initially, small clumps of cancer cells remain within otherwise normal prostate glands, a condition known as carcinoma in situ ... Nutting C, Horwich A, Fisher C, Parsons C, Dearnaley DP (June 1997). "Small-cell carcinoma of the prostate". Journal of the ...
Small cell carcinoma is a very rare (1%[74]) type of prostate cancer that cannot be diagnosed using the PSA.[74][75] As of 2009 ... "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340-1. PMC 1296316 . PMID 9227387.. ... Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in ... LNCaP cells express androgen receptor (AR), but PC-3 and DU-145 cells express very little or no AR. AR, an androgen-activated ...
... fibronectin expression is increased especially in non-small cell lung carcinoma. The adhesion of lung carcinoma cells to ... ISBN 978-0-387-97050-9. Han S, Khuri FR, Roman J (January 2006). "Fibronectin stimulates non-small cell lung carcinoma cell ... The RGD sequence (Arg-Gly-Asp) is located in III10 and is the site of cell attachment via α5β1 and αVβ3 integrins on the cell ... Fibronectin has been implicated in carcinoma development. In lung carcinoma, ...
See also: Combined small-cell lung carcinoma. The term "combined small-cell lung carcinoma" (c-SCLC) refers to a multiphasic ... In contrast, non-small cell lung carcinomas (NSCLC's) are more likely to remain localized to the thorax during development, and ... oncologists have long tended to favor a dichotomous division into small cell and non-small cell forms, based on differences in ... While there have been no randomized clinical trials of targeted agents in combined small-cell lung carcinoma (c-SCLC),[citation ...
1977). "Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports 61 (3): 349-354. PMID 194691. ... Detailed guide: Lung cancer - small cell American Cancer Society ((. en. )). *Detailed guide: Lung cancer - non-small cell ... Većina tipova plućnih kancera su plućni karcinomi malih-ćelija (engl. small-cell lung carcinoma, SCLC). Najčešći simptomi su ... Aviel-Ronen, S; Blackhall FH, Shepherd FA, Tsao MS (July 2006). "K-ras mutations in non-small-cell lung carcinoma: a review". ...
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Mignogna MD, Fortuna G, Satriano AR (December 2008). "Small-cell lung cancer and necrolytic migratory erythema". The New ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ... swollen epidermal cells and necrosis of the superficial epidermis are most characteristic. Immunofluorescence is usually ...
... is typically a squamous cell carcinoma. Other types include adenocarcinoma, small cell carcinoma, and melanoma. ... Most anal cancers are squamous cell carcinomas (epidermoid carcinomas), that arises near the squamocolumnar junction. It may be ... Dewdney A, Rao S (2012). "Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?". ISRN ... Human papillomavirus: Examination of squamous cell carcinoma tumor tissues from patients in Denmark and Sweden showed a high ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with Paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
NSE is produced by small-cell carcinomas, which are neuroendocrine in origin. NSE is therefore a useful tumor marker for ... "Molecular characterization of prostatic small-cell neuroendocrine carcinoma". Prostate. 55 (1): 55-64. doi:10.1002/pros.10217. ... distinguishing small-cell carcinomas from other tumors. GRCh38: Ensembl release 89: ENSG00000111674 - Ensembl, May 2017 GRCm38 ... Detection of NSE with antibodies can be used to identify neuronal cells and cells with neuroendocrine differentiation. ...
NSE is produced by small-cell carcinomas, which are neuroendocrine in origin. NSE is therefore a useful tumor marker for ... "Molecular characterization of prostatic small-cell neuroendocrine carcinoma". Prostate. 55 (1): 55-64. doi:10.1002/pros.10217. ... Detection of NSE with antibodies can be used to identify neuronal cells and cells with neuroendocrine differentiation. ... neuronal cell body. • perikaryon. • intracellular. • myelin. Biological process. • gluconeogenesis. • canonical glycolysis. • ...
... small cell carcinoma of the prostate, in turn, exhibit a universal type in that virtually all the constituent tumor cells ... June 2006). "Small cell carcinoma of the prostate: an immunohistochemical study". The American Journal of Surgical Pathology. ... Immunohistochemically, prostatic small cell carcinoma are positive for thyroid transcription factor 1 (TTF-1), CD56, ... These types of prostate cancer comprise true neuroendocrine cancers, such as small cell carcinoma, carcinoid and carcinoid-like ...
Ectopic ACTH syndrome, also known as small-cell carcinoma. Ectopic calcification, a pathologic deposition of calcium salts in ... such as small-cell carcinoma, can cause Cushing's syndrome Ectopia lentis, the displacement of the crystalline lens of the eye ...
Syrian hamsters are a model for researching Non-small-cell lung carcinoma, which is one of the types of human lung cancer. In ... "Current role of surgery in small cell lung carcinoma". Journal of Cardiothoracic Surgery. 4 (1): 30. doi:10.1186/1749-8090-4-30 ... Oral squamous-cell carcinoma is a common cancer in humans and difficult to treat. Scientists studying this disease broadly ... The scientist can take cell samples from the mouth of the hamster to measure the development of the cancer. This process has ...
Mary A. McClure, 77, American politician, small-cell carcinoma. Carlos Morocho Hernández, 76, Venezuelan WBA and WBC super ... desmoplastic small-round-cell tumor. Sheilla Lampkin, 70, American politician, member of the Arkansas House of Representatives ... Paddy Phelan, 78, English cricketer (Essex). Anita Reeves, 68, Irish actress (Dancing at Lughnasa, Little Gem), cancer. Wolfram ... sumo's small great 'Wolf,' dies Thomas Edward Danson Jr. Tributes paid to renowned poet and vicar Gwynn ap Gwilym Archived ...
show that two genes encoding for has-miR-9 are significantly hypermethylated in clear cell renal carcinoma tumours. Ambros V ( ... 2001). "microRNAs: tiny regulators with great potential". Cell. 107 (7): 823-6. doi:10.1016/S0092-8674(01)00616-X. PMID ... Uchida N (2010). "MicroRNA-9 controls a migratory mechanism in human neural progenitor cells". Cell Stem Cell. 6 (4): 294-6. ... "MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors". Cell Stem Cell. 6 ...
Small Cell Lung Carcinoma (SCLC) is the most closely associated with almost 100% of cases occurring in smokers.[56] This form ... If the mutation inhibits programmed cell death, the cell can survive to become a cancer, a cell that does not function like a ... If the mutation inhibits programmed cell death, the cell can survive to become a cancer cell. Similarly, acrolein, which is ... Lipworth L, Tarone RE, McLaughlin JK (December 2006). "The epidemiology of renal cell carcinoma". The Journal of Urology. 176 ( ...
A promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells". ... oral squamous cell carcinoma,[11] in glioblastome multiforme cells [12] and colon cancer cell lines.[13][14][15][16] Honokiol ... As a polyphenol it is relatively small and can interact with cell membrane proteins through intermolecular interactions like ... Honokiol also acts on the PI3K/mTOR pathway in tumor cells while maintaining pathway activity in T cells.[17] ...
"Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma". Br. J. Cancer. 96 ... cell adhesion. • positive regulation of osteoblast differentiation. • chondrocyte proliferation. • positive regulation of cell ... Cell Genet. 61 (4): 274-5. doi:10.1159/000133421. PMID 1486804.. *. Abedinia M, Layfield R, Jones SM, Nixon PF, Mattick JS ( ... extracellular domain in pichia pastoris and functional analysis in synovial fibroblasts and NIT3T3 cells". Mol. Cell. Biochem. ...
Gronowitz JS, Steinholtz L, Källander CF, Hagberg H, Bergh J (1986). "Serum deoxythymidine kinase in small cell carcinoma of ... is cell cycle-independent. TK1 is synthesized by the cell during the S phase of cell division. After cell division is completed ... Another reason is that lung cancer, particularly small cell lung cancer, is very aggressive with very low 5 year survival rates ... Cells prepare for cell division by making some of the enzymes required during the division. They are not normally present in ...
Hietanen S, Lain S, Krausz E, Blattner C, Lane DP (2000). "Activation of p53 in cervical carcinoma cells by small molecules". ... However, recent data shows that leptomycin causes G1 cell cycle arrest in mammalian cells and is a potent anti-tumor agent ... Cell Res. 242 (2): 540-7. doi:10.1006/excr.1998.4136. PMID 9683540. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, ... Leptomycin B was found to cause cell elongation of the fission yeast Schizosaccharomyces pombe. Since then this elongation ...
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007 Feb;26(7):1046. Dierks C, Beigi R, ... Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell ... Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996 Jun 14;85(6):841- ... interferes with growth and invasion of human renal cell carcinoma cells. British journal of cancer. 2014 Sep;111(6):1168. ...
... and other cells have shown that PC3 is characteristic of small cell neoendocrine carcinoma. PC3 cells have low testosterone-5- ... "PC3 is a cell line characteristic of prostatic small cell carcinoma". The Prostate. 71 (15): 1668-79. doi:10.1002/pros.21383. ... PC3 cells are also used to study viral infection in mammalian cells that exhibit an immune response The PC3 cell line was ... PC3 cells are useful in investigating biochemical changes in advanced prostate cancer cells and in assessing their response to ...
F9 embryonal carcinoma cells are similar to the P19 cells shown in Figure 1 and normally have cell-to-cell adhesion mediated by ... In F9 cells lacking both β-catenin and plakoglobin, very little E-cadherin and α-catenin accumulated at the cell surface. Mice ... A tumor cell line with defective δ-catenin, low levels of E-cadherin and poor cell-to-cell adhesion could be restored to normal ... Catenin and EMT interactions may also play a role in hepatocellular carcinoma. VEGF-B treatment of hepatoma carcinoma cells can ...
squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ... Microneedling is a procedure in which an instrument with multiple rows of tiny needles is rolled over the skin to elicit a ... and Th1 cells.[45] IL-1α stimulates increased skin cell activity and reproduction, which, in turn, fuels comedo development.[45 ... and accumulation of skin cells in the hair follicle.[1] In healthy skin, the skin cells that have died come up to the surface ...
Oral carcinoma[edit]. Patients after HSCT are at a higher risk for oral carcinoma. Post-HSCT oral cancer may have more ... Researchers have conducted small studies using non-myeloablative hematopoietic stem cell transplantation as a possible ... who have lost their stem cells after birth. Other conditions[13] treated with stem cell transplants include sickle-cell disease ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ...
... almost all subtypes of renal cell carcinoma, nephrogenic adenomas, ovarian cancer cells, bladder, prostate, and endometrial ... aka Hurthle-Cell Neoplasms).[15] Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present ... regulation of metanephric nephron tubule epithelial cell differentiation. • cell differentiation. • mesonephric tubule ... positive regulation of metanephric DCT cell differentiation. • negative regulation of mesenchymal cell apoptotic process ...
... , sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). ... It has received regulatory approval for use as a treatment for non-small cell lung cancer,[6][4][7][8] although there is ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ... "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147-157. doi:10.2147/ ...
The removal of cells for biopsy, using a needle Clinical features[edit]. Clinical features can be found in the subhyoid portion ... Thyroglossal duct cyst carcinoma[edit]. Rarely, cancer may be present in a thyroglossal duct cyst. These tumors usually arise ... In some individuals, portions of the duct remain behind, leaving small pockets, known as cysts. During a person's life, these ... Thyroglossal cysts can be defined as an irregular neck mass or a lump which develops from cells and tissues left over after the ...
Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells ... However, a smaller tumor in an area such as Wernicke's area (small area responsible for language comprehension) can result in a ... Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ... Necrotic cells send the wrong chemical signals which prevent phagocytes from disposing of the dead cells, leading to a buildup ...
"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells ... William Figg; Cindy H. Chau; Eric J. Small (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business ... G. Raspé; W. Brosig (22 October 2013). International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November ... Cell Biol. 42 (6): 813-27. doi:10.1016/j.biocel.2009.11.013. PMID 19931639.. ...
... or tumors such as lymphoma or squamous cell carcinoma. A tonsillolith (also known as a "tonsil stone") is material that ... No crypts, but small folds. Roof of pharynx Tubal tonsils. Ciliated pseudostratified columnar (respiratory epithelium). Roof of ... These M cells then alert the underlying B cells and T cells in the tonsil that a pathogen is present and an immune response is ... The tonsils have on their surface specialized antigen capture cells called M cells that allow for the uptake of antigens ...
Thus, in most cases, small amounts of BaP are metabolized prior to being passed into the blood.[citation needed] The lungs are ... BaP was shown to cause genetic damage in lung cells that was identical to the damage observed in the DNA of most malignant lung ... In the 18th century a scrotal cancer of chimney sweepers, the chimney sweeps' carcinoma, was already known to be connected to ... BaP has an effect on the number of white blood cells, inhibiting some of them from differentiating into macrophages, the body's ...
Esophageal squamous cell cancer. Over-expression. 47%. Immunohistochemistry. [24]. Renal cell carcinoma. Under-expression. 100% ... Non-small-cell lung cancer. Over-expression. 29%. Immunohistochemistry. [22]. Soft tissue sarcoma. Over-expression. 95%. ... of non-small cell lung cancers,[45] and 36% of colon cancers.[46] miR-34a is also generally under-expressed in primary ... "High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients". Br. J. ...
Basal cell carcinoma Fleshy, growing mass Areas exposed to the sun Squamous cell carcinoma Unusual growth that is red, scaly or ... Small, firm, round bumps with pits in the center that may sit on tiny stalks Anywhere ... Small red dots on the skin, or larger, bruise-like spots that appeared after taking medicine Anywhere ... Started with a single scaly, red and slightly itchy spot, and within a few days, did large numbers of smaller patches of the ...
Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003, 361 (9371): 1810-2. PMID ... Gynecologic ultrasonography, specifically looking for small ovarian follicles. These are believed to be the result of disturbed ... and interleukin-1 in modulating progesterone and oestradiol production by human luteinized granulosa cells in culture. Hum. ... 12 or more small follicles should be seen in an ovary on ultrasound examination.[52]More recent research suggests that there ...
Small intestine cancer. *Small-cell carcinoma. *Soft-tissue sarcoma. *Spinal tumor. *Squamous cell carcinoma ...
Binding of AMP at this site, corresponding in a change from the T state of the enzyme to the R state, results in small changes ... The glycogen phosphorylase monomer is a large protein, composed of 842 amino acids with a mass of 97.434 kDa in muscle cells. ... Shimada S, Matsuzaki H, Marutsuka T, Shiomori K, Ogawa M (July 2001). "Gastric and intestinal phenotypes of gastric carcinoma ... In fact, 70% of dimeric phosphorylase in the cell exists as bound to glycogen granules rather than free floating.[9] ...
Small lymphocytes 7-8. Large lymphocytes 12-15. *B cells: releases antibodies and assists activation of T cells ... carcinoma ... T cells: *CD4+ helper T cells: T cells displaying co-receptor ... Natural killer cells: virus-infected and tumor cells.. Deeply staining, eccentric. NK-cells and cytotoxic (CD8+) T-cells. Years ... CD8+ cytotoxic T cells: T cells displaying co-receptor CD8 are known as CD8+ T cells. These cells bind antigens presented on ...
It is also used to prevent certain skin cancers (squamous-cell carcinoma), and in the treatment of other cancers. It is used to ... It is a retinoid, meaning it is related to vitamin A, and is found in small quantities naturally in the body. Its isomer, ... Cell death may be instigated in the meibomian glands,[30][55] hypothalamic cells,[56] hippocampus cells[57][58] and-important ... programmatic cell death) in various cells in the body. ... suppresses hippocampal cell survival in mice". Annals of the ...
... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells". Molecular Pharmacology. 75 (1): 196-207. ... Paracrine signaling is a form of cell-cell communication in which a cell produces a signal to induce changes in nearby cells, ... These T cells can then go on to perform effector functions such as macrophage activation, B cell activation, and cell-mediated ...
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band ... Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III ... Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer ... EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398-406, doi:10.1016/j.eururo. ...
O குருதி வகையானது squamous cell carcinoma வருவதற்கான சூழிடர் 14% குறைவாகவும், basal cell carcinoma வருவதற்கான சூழிடர் 4% ... The highest frequencies are found in small, unrelated populations. For example, about 80% of the Blackfoot Indians of Montana ... Dean L (2005). "Chapter 5: The ABO blood group.". Blood Groups and Red Cell Antigens. பார்த்த நாள் 2007-03-24. ... Laura Dean, MD (2005). Blood Groups an Red Cell Antigens. National Center for Biotechnology Information, United States ...
1983). "Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture". Biol Cell. ... resembles the enterocytes lining the small intestine.[2][3] Caco-2 cells express tight junctions, microvilli, and a number of ... Caco-2 cells are most commonly used not as individual cells, but as a confluent monolayer on a cell culture insert filter (e.g ... 2005). "The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell ...
PTCH1 (Nevoid basal-cell carcinoma syndrome). *BMPR1A (BMPR1A juvenile polyposis syndrome). *IL2RG (X-linked severe combined ... If the pre-treatment testes are very small and there has been a history of undescended testes it might take longer to achieve ... LHCGR (Luteinizing hormone insensitivity, Leydig cell hypoplasia, Male-limited precocious puberty). *FSHR (Follicle-stimulating ... "The Smallest Kid in School: Evaluating Delayed Puberty". Medscape Pediatrics.. *^ a b Jones H, ed. (2008). "Chapter 9: Puberty ...
Gankyrin is anti-apoptotic and has been shown to be overexpressed in some tumor cell types such as hepatocellular carcinoma.[81 ... The small pink spheres represent the location of the active-site threonine residue in each subunit. Light blue chemical ... "Cell. 137 (1): 133-45. doi:10.1016/j.cell.2009.01.041. PMC 2668214. PMID 19345192.. ... Cell cycle controlEdit. Cell cycle progression is controlled by ordered action of cyclin-dependent kinases (CDKs), activated by ...
The common house mold, Trichoderma longibrachiatum, produces small toxic peptides containing amino acids not found in common ... This affects in the cells action potential profile, as seen in cardiomyocytes, pneumocytes and neurons leading to conduction ... "Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment". Environmental Health Perspectives. 118 (6): ... McCormick A, Loeffler J, Ebel F (November 2010). "Aspergillus fumigatus: contours of an opportunistic human pathogen". Cell. ...
"Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ... Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor ...
Small-cell carcinoma. *Transitional cell carcinoma. Penis. *Carcinoma *Extramammary Paget's disease. *Bowen's disease ... A seminoma is a germ cell tumor of the testicle or, more rarely, the mediastinum or other extra-gonadal locations. It is a ... Weidner N (February 1999). "Germ-cell tumors of the mediastinum". Seminars in Diagnostic Pathology. 16 (1): 42-50. PMID ... Testicular seminoma originates in the germinal epithelium of the seminiferous tubules.[2] About half of germ cell tumors of the ...
"Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma". American Journal of Pathology. 134 (6): ... A small pilot study suggested possible benefit from the tyrosine kinase inhibitor erlotinib in people with advanced ... the actual cell of origin is unknown. Recent evidence has suggested that the initial transformed cell that generates the ... Micrograph of an intrahepatic cholangiocarcinoma (right of image) adjacent to normal liver cells (left of image). H&E stain. ...
Treatment of renal cell carcinoma with infliximab resulted in prolonged disease stabilization in certain patients. Etanercept ... positive regulation of heterotypic cell-cell adhesion. • negative regulation of mitotic cell cycle. • endothelial cell ... but it is produced also by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells, cardiac ... NK cells, neutrophils, mast cells, eosinophils, and neurons.[5] TNFα is a member of the TNF superfamily, consisting of various ...
Due to its anatomy, the pinna largely eliminates a small segment of the frequency spectrum; this band is called the pinna notch ... benign and malignant neoplasm, including tumors, keratoacanthoma, carcinoma[5]. Additional images[edit]. *. ... These portions of the ear are supplied by the cervical plexus and a small portion by the facial nerve. This explains why ... The fennec fox uses its distinctive oversized pinnae to radiate excess heat and to amplify the sound of small prey burrowing ...
For example: non-melanoma skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, anal ... 2005). "Cervix carcinoma". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium ... Targeting double-stranded breaks increases the probability that cells will undergo cell death. Cancer cells are generally less ... Fractionation allows normal cells time to recover, while tumor cells are generally less efficient in repair between fractions. ...
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Large-cell lung carcinoma[edit]. Main article: Large-cell lung carcinoma. Large cell lung carcinoma (LCLC) is a heterogeneous ... using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors.[30] ... Pie chart showing incidences of non-small cell lung cancers as compared to small cell carcinoma shown at right, with fractions ...
... also called oat cell carcinoma, can create its own hormones, which alter body chemistry. ... Small cell carcinoma, also called oat cell carcinoma, can create its own hormones, which alter body chemistry. ...
Non-small cell carcinomas are the most common lung cancers. ...
... as extrapulmonary small cell carcinoma (EPSCC). Small cell carcinoma is a distinct clinical and pathologic entity that arises ... it is not uncommon for these cells to arise in nonpulmonary sites, ... from cells of the amine precursor uptake and decarboxylation (APUD) system. ... Small cell carcinomas (SCC) commonly arise in the respiratory tract; however, ...
This article reviews the recent literature on extrapulmonary small cell carcinomas. Until now, only four cases have been ... Small cell carcinoma of the skin is included. This form of small cell carcinoma is often excluded from the larger review series ... Carcinoma, Merkel Cell* / drug therapy, mortality, pathology. Carcinoma, Small Cell* / mortality, pathology, therapy. Diagnosis ... This article reviews the recent literature on extrapulmonary small cell carcinomas. Until now, only four cases have been ...
... Daniel J. Oh,1 Ellen Dinerman,1 Andrew H. Matthews,1 Abraham W. ... She was later diagnosed with small cell carcinoma of the lung. Conclusions. In this case report, we describe a critically ill ... However, its presence in solid tumors such as small cell carcinoma of the lung has been reported rarely [1-5]. Even fewer cases ... Bronchoscopy revealed purulent secretions and biopsy of the mass demonstrated small cell carcinoma. The CT abdomen revealed a ...
Primary Small Cell Neuroendocrine Carcinoma of Vagina: A Rare Case Report. Jignasa N. Bhalodia,1 Dhiren V. Kapapura,2 and Malay ... Jignasa N. Bhalodia, Dhiren V. Kapapura, and Malay N. Parekh, "Primary Small Cell Neuroendocrine Carcinoma of Vagina: A Rare ...
Non-Small Cell Lung CarcinomaA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better ... Non-Small Cell Lung CarcinomaTrial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer NCT00321308 ... Non-Small Cell Lung CarcinomaEvaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The ... Non-Small Cell Lung CarcinomaPH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line ...
Non-Small-Cell Lung CarcinomaA Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib ... Non-Small-Cell Lung CarcinomaAn Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell ... Non-Small-Cell Lung CarcinomaStudy Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer NCT00092001 ... Non-Small-Cell Lung CarcinomaMEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer NCT00174369 ...
Diseases : Carcinoma: Non-Small-Cell Lung, Carcinoma: Small Cell Lung, Lung Cancer, Lung Cancer: Metastatic ... Ganoderma is cytotoxic to both drug-sensitive and drug-resistant small-cell lung carcinoma cells and can reverse resistance to ... Diseases : Carcinoma: Small Cell Lung, Colon Cancer, Lung Cancer, Nasopharyngeal Cancer. Pharmacological Actions : Anti- ... Diseases : Carcinoma: Small Cell Lung, Nicotine/Tobacco Toxicity Pharmacological Actions : Angiogenesis Inhibitors, Anti- ...
... tells Yahoo Entertainment that tests have determined the former child star has stage IV small cell carcinoma cancer after his ... Dustin Diamond completes first round of chemo amid stage IV small cell carcinoma diagnosis. Suzy Byrne. ·Editor, Yahoo ... Dustin Diamond has stage 4 small cell carcinoma, according to his rep. He had been diagnosed with cancer earlier this month. ( ... tells Yahoo Entertainment that tests have determined the former child star has stage IV small cell carcinoma cancer after his ...
Histologically, this type has sheets of highly atypical cells with focal... more ... Large-cell carcinoma accounts for 10-15% of lung cancers, typically manifesting as a large peripheral mass on chest radiograph ... Drugs & Diseases , Oncology , Non-Small Cell Lung Cancer (NSCLC) Q&A How is large-cell carcinoma subtype of non-small cell lung ... Non-small cell lung cancer. Left pleural effusion and volume loss secondary to non-small cell carcinoma of the left lower lobe ...
... but Memorial Sloan Kettering experts have experience treating both large cell neuroendocrine carcinoma and small cell carcinoma ... Gastrointestinal small cell carcinoma and large cell carcinoma are usually diagnosed at an advanced stage, after they have ... The following tests may be performed to confirm a diagnosis of large cell neuroendocrine carcinoma or small cell carcinoma. ... Because small cell and large cell neuroendocrine carcinomas of the gastrointestinal tract are usually found at an advanced ...
Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of ... Primary small cell carcinoma of the urinary bladder. October 8, 2019 Small cell carcinoma of the urinary bladder (SCCB) is an ... Diagnosis of SCCB is based on the WHO criteria for small cell lung carcinoma. A 58-year-old man who had presented with ... It is often misdiagnosed as transitional cell carcinoma, owing to the similarities in presentation. ...
Diseases : Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Antiproliferative , Apoptotic, Cell cycle arrest, Tumor ... Diseases : Cancers: Drug Resistant, Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Antineoplastic Agents, Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Anti-metastatic, Antiproliferative , Cell ...
Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma. L C Rosenbaum, E A Neuwelt, H H ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ...
... the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen ... of a panel of 60 human tumor cell lines with an HH antagonis … ... Non-Small-Cell Lung / drug therapy * Carcinoma, Non-Small-Cell ... Frequent requirement of hedgehog signaling in non-small cell lung carcinoma Oncogene. 2007 Feb 15;26(7):1046-55. doi: 10.1038/ ... Carcinoma, Non-Small-Cell Lung / classification * Carcinoma, ... the dependence of non-small cell lung carcinomas (NSCLC) for HH ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Thymic carcinoma. Small cell carcinoma. Reviewer: Hanni Gulwani, M.D. (see Reviewers page). Revised: 9 March 2013, last major ... Lymphoma: keratin-, CD45+ End of Mediastinum > Thymic carcinoma > Small cell carcinoma. This information is intended for ... Also called oat cell carcinoma, undifferentiated neuroendocrine carcinoma Sites. ... Clusters of small blue cells with minimal cytoplasm, hyperchromatic nuclei, no / minimal nucleoli, nuclear molding, frequent ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
One hundred forty-eight patients with small cell carcinoma of the lung had und … ... In an attempt to define the role of initial surgical resection in patients with undifferentiated small cell carcinoma of the ... Surgical resection in the management of small cell carcinoma of the lung J Thorac Cardiovasc Surg. 1982 Oct;84(4):481-8. ... In an attempt to define the role of initial surgical resection in patients with undifferentiated small cell carcinoma of the ...
Pathology obtained from transurethral resection of the prostate revealed pure small cell carcinoma of the prostate. ... An Unusual Etiology of Urinary Retention - Small Cell Prostate Carcinoma June 29, 2016 We report the case of a 63-year-old male ... Small cell carcinoma is an aggressive variant of prostate cancer that often presents late in the clinical course. We review the ... Pathology obtained from transurethral resection of the prostate revealed pure small cell carcinoma of the prostate. Metastatic ...
Small cell carcinoma information including symptoms, causes, diseases, symptoms, treatments, and other medical and health ... Small cell carcinoma. Description of Small cell carcinoma. Small cell carcinoma: highly malignant carcinoma composed of small ... Terms Similar to Small cell carcinoma:. *oat cell carcinoma Source - WordNet 2.1 Broader terms for Small cell carcinoma. * ... Small cell *Small *Small syndrome *Cell *Carcinoma *Anaplastic *Malignant *Bronchogenic *Ovoid *Cytoplasm Terms associated with ...
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY). The safety and scientific validity of this study is the ... Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res ...
After Phil Gonzalez was diagnosed with squamous cell carcinoma in the left side of his jaw, he came to MD Anderson. But Phil ... After Phil Gonzalez was diagnosed with squamous cell carcinoma in the left side of his jaw, he came to MD Anderson. But Phil ... Phil had squamous cell carcinoma of the left mandible, a type of head and neck cancer. He quickly scheduled an appointment with ... During his squamous cell carcinoma treatment, his wife brought him his favorite food, a banana split, but he couldnt taste it ...
... invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell ... lung carcinomas (NSCLC) and certain other human carcinomas. ... cultured cells from a non-small cell lung carcinoma, and (3) ... human lung carcinoma cells from pleural effusions or cultured cells from human non-small cell lung carcinoma, or cells from a ... Lung Carcinoma. Adeno 18/19. Squamous 8/10. Small Cell 2/6. Large Cell 2/2. Breast Carcinoma 13/16. Colon Carcinoma 9/9. ...
PubMed journal article Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrenc were found in PRIME ... Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrence.. Int J Surg Pathol 2009; 17(1):46-50IJ ... Small Cell Carcinoma: Arising in Lynch Syndrome: a Previously Undocumented Occurrence. Int J Surg Pathol. 2009;17(1):46-50. ... Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrence. Int J Surg Pathol. 2009;17(1):46-50. ...
"A combined small cell carcinoma of the lung containing three components: small cell, spindle cell and squamous cell carcinoma ... Small-cell carcinoma is most often more rapidly and widely metastatic than non-small-cell lung carcinoma (and hence staged ... Compared to non-small cell carcinoma, small cell carcinoma has a shorter doubling time, higher growth fraction, and earlier ... Although combined small-cell lung carcinoma is currently staged and treated similarly to "pure" small-cell carcinoma of the ...
Small Cell Carcinoma of the Ovary, Hypercalcemic Type is a rare and aggressive cancer that typically strikes girls and young ... Small Cell Carcinoma of the Ovary, Hypercalcemic Type - Clinical Trials Fund. .BBFormSelectList{text-transform: capitalize;}. ... It is also the average age of diagnosis for small cell carcinoma of the ovaries hypercalcemic type (SCCOHT) - a highly ... Today, we ask you to join our fight against ovarian cancer by supporting TGens Small Cell Ovarian Cancer Clinical Trial. ...
... little is known about how to prevent it. Recently this type of lung cance ... Because little is known about the actual cause of bronchoalveolar carcinoma, ... Non-Small Cell Lung Cancer. The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands ... Continue Learning about Non-Small Cell Lung Cancer. Treating Non-Small Cell Lung Cancer with Immunotherapy ...
  • Non-small-cell lung carcinoma ( NSCLC ) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). (wikipedia.org)
  • The most common types of NSCLC are squamous cell carcinoma , large cell carcinoma , and adenocarcinoma , but there are several other types that occur less frequently. (wikipedia.org)
  • [5] Non-squamous cell carcinoma almost occupy the half of NSCLC. (wikipedia.org)
  • LCLC's have typically comprised around 10% of all NSCLC in the past, although newer diagnostic techniques seem to be reducing the incidence of diagnosis of "classic" LCLC in favor of more poorly differentiated squamous cell carcinomas and adenocarcinomas. (wikipedia.org)
  • AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC). (pfizer.com)
  • Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study. (pfizer.com)
  • NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar). (pfizer.com)
  • How is large-cell carcinoma subtype of non-small cell lung cancer (NSCLC) characterized? (medscape.com)
  • Although it had previously been suggested that the hedgehog (HH) pathway might be activated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. (nih.gov)
  • During a screen of a panel of 60 human tumor cell lines with an HH antagonist, we observed that the proliferation of a subset of NSCLC cell lines was inhibited. (nih.gov)
  • These NSCLC cell lines express HH, as well as key HH target genes, consistent with them being activated through an autocrine mechanism. (nih.gov)
  • Interestingly, we also identified a number of NSCLC cell lines that express high levels of the downstream transcription factor GLI1 and harbor enhanced levels of HH activity, but appear insensitive to known HH antagonists. (nih.gov)
  • The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. (freepatentsonline.com)
  • The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. (freepatentsonline.com)
  • The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands of people each year. (sharecare.com)
  • The deleted in liver cancer (DLC-1) gene is a recently identified tumor suppressor gene for human non-small cell lung carcinoma (NSCLC). (cdc.gov)
  • It can inhibit the growth and induce morphological changes of NSCLC cells in gene transfection studies. (cdc.gov)
  • A cDNA array analysis was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCI-H522. (cdc.gov)
  • Among them, downregulation of tyrosine protein kinase ABL2 (ABL2) gene and upregulation of hint/protein kinase C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1 genes were found in expanded observations in two or three of five 5-aza-dC-treated NSCLC cell lines. (cdc.gov)
  • Among these genes, we found that cDNA transfer of Hint/PKCI-1 resulted in a significant in vitro growth inhibition in two cell lines exhibiting 5-aza-dC-induced upregulation of Hint/PKCI-1 and significantly reduced in vivo tumorigenicity of one NSCLC cell line. (cdc.gov)
  • Non-small Cell Lung Carcinoma is also known as non-small cell lung carcinoma, nonsmall cell lung cancer, nsclc, non-small cell lung cancer (disorder), carcinoma, non-small-cell lung, carcinoma non-small cell lung, carcinoma of lung. (novusbio.com)
  • 78.28% (292) were non-small-cell lung carcinoma (NSCLC) of which 59.58% (174) had a study of markers being 35.05 positive (61). (ersjournals.com)
  • Nonsquamous-cell carcinoma almost occupies the half of NSCLC. (wikipedia.org)
  • Recently, crizotinib, a small molecule inhibitor of ALK, was shown to selectively inhibit the growth of ALK-positive NSCLC ( 6 - 8 ), indicating that a subclass of NSCLC patients are likely to benefit clinically from an ALK inhibitor. (spandidos-publications.com)
  • However, since the incidence of ROS1 or RET fusions is less than that of ALK fusions in NSCLC, only a small number of NSCLC patients with ROS1 or RET fusions has thus far been identified. (spandidos-publications.com)
  • XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC). (pharmacytimes.com)
  • XMT-1536 is a transmembrane sodium-phosphate transporter that is expressed in ovarian carcinoma and NSCLC, as well as other tumors. (pharmacytimes.com)
  • The study is currently enrolling for dose expansion in patients with high-grade serous ovarian carcinoma and NSCLC, adenocarcinoma subtype. (pharmacytimes.com)
  • The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. (scienceblog.com)
  • NSCLC (includes squamous, large cell or adenocarcinoma). (knowcancer.com)
  • Chromosome band 9p21 is deleted frequently in non-small cell lung carcinoma (NSCLC), and the p15 and p16 cyclin-dependent kinase-4 inhibitor genes map within this deletion region. (aacrjournals.org)
  • Recent studies demonstrated deletion of p15 and p16 in NSCLC metastases and cell lines, suggesting a role for these genes in NSCLC progression. (aacrjournals.org)
  • We studied both the antiproliferative and antitumor properties of a fucoidan extract (HF) obtained from the brown seaweed Ascophyllum nodosum on a cell line derived from a non-small-cell human bronchopulmonary carcinoma (NSCLC-N6), this type of carcinoma is particularly chemo-resistant. (nih.gov)
  • Retinoblastoma (RB) protein expression was examined in paraffin and frozen tissue sections of 36 primary non-small cell lung carcinomas (NSCLC) using immunohistochemistry with confirmation by direct Western blotting. (aacrjournals.org)
  • MET, EGFR, and their interaction in NSCLC cell lines. (aacrjournals.org)
  • A, MET and EGFR are coexpressed in a high percentage of NSCLC cell lines. (aacrjournals.org)
  • SGX523 sensitized NSCLC cells to erlotinib in suppressing proliferation in the presence of MET and EGFR ligands in vitro . (aacrjournals.org)
  • The modest response of patients with head and neck squamous cell carcinoma (HNSCC) and non-small cell lung carcinoma (NSCLC) to epithelial growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib indicates the need for the development of biomarkers to predict response. (aacrjournals.org)
  • We confirmed that increased protein expression of vimentin combined with the loss of E-cadherin, claudin 4, and claudin 7 by immunoblotting was associated with gefitinib resistance in both HNSCC and NSCLC cell lines. (aacrjournals.org)
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. (selleckchem.com)
  • Knockdown of BTK sensitized the NSCLC cells to Gefitinib. (selleckchem.com)
  • Meanwhile, the second-generation BTK inhibitor Acalabrutinib effectively suppressed SOX2, STAT3/JAK2/Akt axis and potentiated the anti-proliferative effect of Gefitinib and Osimertinib in NSCLC cells, including the T790M H1975 cells. (selleckchem.com)
  • Our findings suggested that BTK mediates stemness and EMT properties, and inhibition of BTK potentiates the effect of Gefitinib and Osimertinib in NSCLC cells resistant to TKI. (selleckchem.com)
  • However, the syndrome of inappropriate anti-diuretic hormone secretion (SIADH) is rare in non-small cell lung cancer (NSCLC). (ecancer.org)
  • To identify the pattern of IRAK-1 protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions. (pubmedcentralcanada.ca)
  • the two most common NSCLC histologic types are squamous cell carcinoma (SCC) and adenocarcinoma (ADCA) ( 2 ). (pubmedcentralcanada.ca)
  • Both NSCLC histologic types are believed to arise after a sequential progression of premalignant lesions, which include bronchial squamous metaplasias and dysplasias for squamous cell carcinoma, and peripheral atypical alveolar hyperplasias (AAH) for a subset of adenocarcinomas ( 3 ). (pubmedcentralcanada.ca)
  • Attending the seminar, Dr Basma M'Barek, Hy Vong Cancer Care Centre from FV Hospital, shared her experiences on the topic Optimizing When Using Osimertinib in Treating Non-Small-Cell Lung Carcinoma NSCLC & Sharing Treated Cases . (fvhospital.com)
  • our earlier studies had shown that reported ID1 is induced by nicotine or EGF stimulation of non-small cell lung cancer (NSCLC) cells and its down regulation abrogates cell proliferation, invasion and migration. (springer.com)
  • A microarray analysis was done on two different NSCLC cell lines (A549 and H1650) that were transfected with a siRNA to ID1 or a control, non-targeting siRNA. (springer.com)
  • STMN3 and GSPT1 were found to facilitate the proliferation, invasion and migration of NSCLC cells in response to nAChR activation. (springer.com)
  • Compared to non-small cell lung cancer (NSCLC), SCLC is generally more aggressive, with decreased doubling times and faster growth rates. (biomedcentral.com)
  • Aberrant signalling of receptor tyrosine kinases (RTKs), such as c-Met, the receptor for hepatocyte growth factor (HGF), has been implicated in the oncogenesis of various tumours including non-small cell lung carcinoma (NSCLC). (biologists.org)
  • This finding was confirmed in several NSCLC cell lines as well as in HeLa cells. (biologists.org)
  • This prospective observational study estimated the effect of prognostic factors, particularly continued smoking during therapy, on survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum. (jcancer.org)
  • Lung cancer is one of the leading causes of cancer-related deaths worldwide [ 1 - 2 ], with non-small cell lung cancer (NSCLC) representing approximately 75%-85% of all types of lung cancer [ 3 ]. (jcancer.org)
  • In an attempt to define the role of initial surgical resection in patients with undifferentiated small cell carcinoma of the lung, we reviewed the experience of the Veterans Administration Surgical Oncology Group (VASOG). (nih.gov)
  • In these cases, the tumors are classified as combined small cell lung carcinoma (c-SCLC), [7] and are (usually) treated like "pure" SCLC. (wikipedia.org)
  • A few neuroendocrine tumors found in the gastrointestinal tract are made of fast-growing, poorly differentiated cancer cells, and respond to different treatments than those used for carcinoid tumors. (mskcc.org)
  • Small cell carcinoma of the lung (SCLC) together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC) make a group of morphologically identifiable neuroendocrine tumors. (srce.hr)
  • The differential diagnosis of SCLC includes, first of all, other neuroendocrine tumors, and primary or metastatic non-small cell carcinomas. (srce.hr)
  • Primary malignant tumors of the hypopharynx are predominantly squamous cell carcinomas (SqCCs), as primary small-cell carcinoma (SmCC) of the hypopharynx is rare. (spandidos-publications.com)
  • We developed a set of castration-resistant prostate carcinomas xenografts and examined their fidelity to their human tumors of origin. (aacrjournals.org)
  • Two additional RB positive primary tumors have major foci in which all tumor cells showed no RB protein staining. (aacrjournals.org)
  • As extra-pulmonary small cell carcinoma (EPSCC) is a rare entity of tumors, the available treatment recommendations are mainly based on retrospective analyses and deduction from treatment of small cell lung cancer. (springermedizin.de)
  • B, the combination enhanced the suppression of cell proliferation in the tumors derived from the hHGF tg -SCID mice. (aacrjournals.org)
  • Consistent with these findings, murine non-neuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. (aacrjournals.org)
  • LCLC is differentiated from small cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. (wikipedia.org)
  • The diagnostic criteria for EPSCC require that the tumor demonstrate histolgic features of small cell carcinoma in the absence of small cell lung cancer (SCLC). (medscape.com)
  • citation needed] Because SCLC usually metastasizes widely very early on in the natural history of the tumor, and because nearly all cases respond dramatically to chemotherapy and/or radiotherapy, there has been little role for surgery in this disease since the 1970s. (wikipedia.org)
  • In ES-SCLC, platinum-based combination chemotherapy is the standard of care, with radiotherapy added only to palliate symptoms such as dyspnea, pain from liver or bone metastases, or for treatment of brain metastases, which, in small-cell lung carcinoma, typically have a rapid, if temporary, response to whole brain radiotherapy. (wikipedia.org)
  • citation needed] In August 2018, the FDA approved nivolumab to treat patients with metastatic small cell lung cancer (SCLC) who failed to respond to platinum-based chemotherapy and at least one other line of treatment. (wikipedia.org)
  • This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). (clinicaltrials.gov)
  • Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens. (clinicaltrials.gov)
  • In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). (nih.gov)
  • This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in subjects with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy with surgery and/or radiation therapy, and XmAb18087 monotherapy in subjects with extensive-stage small cell lung cancer (SCLC) that has progressed after standard therapies. (centerwatch.com)
  • This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). (go.jp)
  • Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). (go.jp)
  • Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. (aacrjournals.org)
  • Therapeutically, EZH2 inhibition followed by STING agonism enhances T cell recognition and rejection of SCLC in mice. (aacrjournals.org)
  • No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. (biomedcentral.com)
  • This is most often the case when a pathologist examines a small amount of malignant cells or tissue in a cytology or biopsy specimen. (wikipedia.org)
  • Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed epithelial cells in the lung. (wikipedia.org)
  • Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. (wikipedia.org)
  • Research of Non-small Cell Lung Carcinoma has been linked to Malignant Neoplasm Of Lung, Malignant Neoplasms, Lung Neoplasms, Neoplasms, Carcinoma. (novusbio.com)
  • If you have been diagnosed with bronchoalveolar carcinoma, it is important to begin treatment immediately to prevent the malignant tumor from metastasizing (spreading). (sharecare.com)
  • a malignant new growth made up of epithelial cells tending to infiltrate surrounding tissues and to give rise to metastases. (thefreedictionary.com)
  • giant cell carcinoma a poorly differentiated, highly malignant, epithelial neoplasm containing many large multinucleated tumor cells, such as occurs in the lungs. (thefreedictionary.com)
  • Hürthle cell carcinoma a malignant Hürthle cell tumor . (thefreedictionary.com)
  • Primary small-cell carcinoma of the cervix (SCCC) is recognised as a rare and aggressive malignant tumour with poor prognosis. (ovid.com)
  • it says poorly differentiated nueroendrocrine small cell carcinoma. (justanswer.com)
  • Small-cell carcinoma is a variant of poorly differentiated neuroendocrine carcinoma. (ovid.com)
  • Small cell carcinoma of the bladder (SCCB) is a rare, poorly differentiated and aggressive neuroendocrine malignancy [ 1 ]. (jcancer.org)
  • Background: Small cell carcinoma of the bladder (SCCB) is a rare, poorly differentiated neuroendocrine epithelial tumour linked with a more assertive behaviour and poorer outcome than bladder transitional cell carcinoma (TCC). (alliedacademies.org)
  • [13] LCLC is, in effect, a "diagnosis of exclusion", in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. (wikipedia.org)
  • Histologic criteria for diagnosis of extrapulmonary small cell carcinoma are same as those for pulmonary small cell carcinoma: the presence of uniform small cells with sparse cytoplasm, dense nuclei, and inconspicuous nucleoli. (medscape.com)
  • Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. (pfizer.com)
  • Sputum cytology alone will not be acceptable for diagnosis or for cell type classification. (pfizer.com)
  • A rep for the Saved By the Bell alum, 44, tells Yahoo Entertainment that tests have determined the former child star has stage IV small cell carcinoma cancer after his initial cancer diagnosis earlier this month. (yahoo.com)
  • By the time a person gets a diagnosis, small cell lung cancer has typically spread (metastasized) outside of the lungs. (yahoo.com)
  • The following tests may be performed to confirm a diagnosis of large cell neuroendocrine carcinoma or small cell carcinoma. (mskcc.org)
  • Diagnosis of SCCB is based on the WHO criteria for small cell lung carcinoma. (urotoday.com)
  • It is also the average age of diagnosis for small cell carcinoma of the ovaries hypercalcemic type (SCCOHT) - a highly aggressive tumor that kills more than 65 percent of patients within two years of initial diagnosis. (tgen.org)
  • In the remaining 77 patients, histological verification of cytological diagnosis was not made and the patients were treated based on cytological diagnosis of small cell carcinoma. (srce.hr)
  • In 76% of cases (38/50) cytological diagnosis of small cell lung carcinoma was also confirmed histologically. (srce.hr)
  • Postoperatively, pathological diagnosis was embolism in external jugular vein from small cell carcinoma of unknown origin. (nii.ac.jp)
  • A diagnosis of extensive stage small-cell lung cancer was made. (thefreelibrary.com)
  • Aims To test the incidence of the expression of the immunohistochemical markers that aid diagnosis of gastrointestinal tract small cell carcinoma (GI-SmCC) and to evaluate the incidence of mixed endocrine-exocrine carcinomas in GI-SmCC. (bmj.com)
  • The patient had axillary and hepatic metastases at the time of diagnosis, and the clinical course suggests that this tumor behaves in an aggressive fashion, analogous to other small cell neuroendocrine carcinomas. (semanticscholar.org)
  • Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung cancer, both of which tended to be more often centrally located. (wikipedia.org)
  • Like pulmonary small cell carcinoma ( lung cancer ), small cell carcinomas arising from extrapulmonary sites may be associated with paraneoplastic syndromes , notably syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and hypercalcemia . (medscape.com)
  • Extrapulmonary small cell carcinoma may have a similar prognosis to that of small cell lung cancer. (medscape.com)
  • Small cell or carcinoid lung cancer patients are also ineligible. (pfizer.com)
  • Siberian ginseng extracts had atiproliferative activity on various cancer and normal cell lines. (greenmedinfo.com)
  • According to the Cleveland Clinic , "Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. (yahoo.com)
  • It is also the "least common type of lung cancer" and spreads faster than non-small cell lung cancer. (yahoo.com)
  • Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. (medscape.com)
  • Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival. (medscape.com)
  • Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. (medscape.com)
  • Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. (medscape.com)
  • Spontaneous regression of metastatic squamous cell lung cancer. (greenmedinfo.com)
  • Citrus reticulata peel oil inhibits non-small cell lung cancer cell proliferation. (greenmedinfo.com)
  • Shikonin could be a novel therapeutic strategy against non-small cell lung cancer. (greenmedinfo.com)
  • Small cell carcinoma is an aggressive variant of prostate cancer that often presents late in the clinical course. (urotoday.com)
  • Phil had squamous cell carcinoma of the left mandible, a type of head and neck cancer. (mdanderson.org)
  • Extensive stage small cell lung cancer is classified as a rare disorder. (wikipedia.org)
  • Today, we ask you to join our fight against ovarian cancer by supporting TGen's Small Cell Ovarian Cancer Clinical Trial. (tgen.org)
  • Immunotherapies are a category of cancer drugs that work by helping the body's immune system identify and destroy cancer cells. (sharecare.com)
  • What are the different types of non-small cell lung cancer? (sharecare.com)
  • How can I prepare for an appointment for non-small cell lung cancer? (sharecare.com)
  • A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells exposed to 5-aza-2'-deoxycytidine (5-aza-dC). (cdc.gov)
  • Median survival in the group of patients with histologically confirmed small cell cancer was 238 days, for women 250 days, and for men 237 days. (srce.hr)
  • Although the surgical margin was narrow, it was negative for cancer cells. (spandidos-publications.com)
  • What do I need to know about caring for someone with non-small cell cancer? (sharecare.com)
  • My 70 years old father is suffering from small cell carcinoma with superior vena cava (SVC) syndrome and the doctor said that he has limited stage cancer. (ndtv.com)
  • You are absolutely right that Gefitinib is used for Non Small Cell Lung Cancer. (ndtv.com)
  • I do not know what made your treating oncologist prescribe the drug for your father, but there is only one case report in the literature about the use of Gefitinib in Small Cell Lung Cancer. (ndtv.com)
  • Small-cell prostate carcinoma (SCPC) is a lethal variant of prostate cancer. (aacrjournals.org)
  • We characterized unique human prostate cancer xenografts from patients with advanced castration-resistant prostate carcinomas (CRPC) and found significant upregulation of mitotic phase genes, including UBE2C (an anaphase promoting complex-specific E2 conjugating enzyme), and loss of retinoblastoma, cyclin D1, and androgen receptor expression in the SCPC xenografts when compared with xenografts with conventional adenocarcinoma morphology. (aacrjournals.org)
  • Small cell lung cancer, another neuroendocrine tumor, is associated with paraneoplastic syndromes (PNS) in up to 20% of cases, notably the syndrome of inappropriate antidiuretic hormone (SIADH) and Lambert-Eaton myasthenic syndrome. (aad.org)
  • It is more commonly associated with non-small-cell lung cancer, but the temporal association with Bowen's disease in the absence of other chemical or occupational exposure strongly points to a causal role for arsenic in this case of small-cell lung cancer. (thefreelibrary.com)
  • Zurück zum Zitat Brennan SM, Gregory DL, Stillie A et al (2010) Should extrapulmonary small cell cancer be managed like small cell lung cancer? (springermedizin.de)
  • Listen as Dr. London Smith (.com) and his producer Cameron discuss Small Cell Lung Cancer with special guest Dr. Benjamin Evans. (stitcher.com)
  • It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. (go.jp)
  • Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. (selleckchem.com)
  • This case indicates that metastasis induced acute pancreatitis can be a manifestation of lung cancer, especially in small cell carcinoma. (eurekamag.com)
  • The frequencies of micronuclei were measured in lymphocytes of 6 patients with small cell lung cancer treated with a combination of cisplatin and etoposide and 7 patients with ovarian carcinoma treated with a combination of taxol and cisplatin. (ovid.com)
  • Utility of PET-CT in non-small cell lung cancer clinical stage IB-IIA according to AJCC 8th edition staging system: an alternative to invasive mediastinal staging? (ecancer.org)
  • get your pathology reviewed to see if it is a small cell lung cancer or neuroendocrine carcinoid tumor from your small bowel. (justanswer.com)
  • A form of cancer , carcinoma makes up the majority of the cases of malignancy of the breast, uterus, intestinal tract, skin, and tongue. (thefreedictionary.com)
  • basal cell carcinoma the most common form of skin cancer, consisting of an epithelial tumor of the skin originating from neoplastic differentiation of basal cells , rarely metastatic but locally invasive and aggressive. (thefreedictionary.com)
  • To develop reliable nomograms to estimate individualized overall survival (OS) and cancer specific survival (CSS) for patients with primary small cell carcinoma of the bladder (SCCB) and compare the predictive value with the AJCC stages. (jcancer.org)
  • Background: The ultimate goal of the study was to find a role of curcumin in targeting lung cancer stem cells by reducing their self-renewal efficiency causing DNA damage. (eurekaselect.com)
  • Materials and Methods: Circulating lung cancer stem cells were isolated by sphere formation assay and further analysed by flow-cytometry and qRT-PCR for the presence of stem cell and stem cell transcription markers. (eurekaselect.com)
  • Results and Conclusion: Our results demonstrated that curcumin significantly affect the self-renewal ability of circulating lung cancer stem cells. (eurekaselect.com)
  • Thus, we can conclude that curcumin can be used to target lung cancer stem cells which is responsible for the disease progression and metastasis by causing DNA damage or inhibiting their DNA repair mechanisms. (eurekaselect.com)
  • Sheefa Mirza, Aakanksha Vasaiya, Hemangini Vora, Nayan Jain and Rakesh Rawal*, "Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma", Anti-Cancer Agents in Medicinal Chemistry (2017) 17: 859. (eurekaselect.com)
  • In Vietnam, lung cancer has one of the highest death rates, with non-small-cell lung carcinoma accounting for 85% of patients being treated. (fvhospital.com)
  • Background and Purpose: Small cell carcinoma of the esophagus (SCEC) is a rare subtype of esophageal cancer for which optimal treatment is unknown. (eur.nl)
  • Sattler and Salgia, 2007 ) so that a detailed understanding of processes underlying c-Met-dependent cancer cell migration is important for providing opportunities for the development of new treatments for these diseases. (biologists.org)
  • We propose that TFP might be capable of inhibiting one or more elements of the DNA DSB repair machinery, thereby increasing the cytotoxicity of bleomycin in lung cancer cells. (diva-portal.org)
  • A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. (semanticscholar.org)
  • TTF-1 positive small cell cancers: Don't think they're always primary pulmonary! (medscape.com)
  • Primary small cell carcinoma of the urinary bladder. (urotoday.com)
  • A case report of primary small cell carcinoma of the breast and review of the literature. (biomedsearch.com)
  • Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid progression and poor prognosis. (biomedsearch.com)
  • Primary small cell carcinoma (SCC) of the breast is a subtype of neuroendocrine carcinoma. (biomedsearch.com)
  • hepatocellular carcinoma primary carcinoma of the liver cells with hepatomegaly, jaundice, hemoperitoneum, and other symptoms of the presence of an abdominal mass. (thefreedictionary.com)
  • Two cases of primary small cell carcinoma of the breast showing non-mass-like pattern on diagnostic imaging and histopathology. (semanticscholar.org)
  • An extremely rare case of primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus is herein presented. (springer.com)
  • Histopathology revealed a primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus. (springer.com)
  • Pie chart showing incidences of non-small cell lung cancers as compared to small cell carcinoma shown at right, with fractions of smokers versus non-smokers shown for each type. (wikipedia.org)
  • Non-small cell carcinomas are the most common lung cancers. (medlineplus.gov)
  • Approximately 1000 cases of extrapulmonary small cell carcinoma are reported annually in the United States, with an overall incidence of 0.1-0.4% of all cancers and 2.5-5% of all small cell carcinomas. (medscape.com)
  • Large-cell carcinoma accounts for 10-15% of lung cancers, typically manifesting as a large peripheral mass on chest radiograph. (medscape.com)
  • [ 11 ] Large-cell undifferentiated cancers carry the same prognosis as do adenocarcinomas and are combined with them in clinical trials. (medscape.com)
  • Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. (greenmedinfo.com)
  • lung cancers are frequently oat cell carcinomas. (rightdiagnosis.com)
  • A neuroendocrine tumour that comprises ±5% of thyroid cancers, arising in the C (parafollicular) cells of the ultimobranchial cleft-i.e., neural crest origin. (thefreedictionary.com)
  • Can bronchoalveolar carcinoma be prevented? (sharecare.com)
  • Because little is known about the actual cause of bronchoalveolar carcinoma, little is known about how to prevent it. (sharecare.com)
  • How do I manage bronchoalveolar carcinoma on a daily basis? (sharecare.com)
  • Because bronchoalveolar carcinoma cells are known to be spread out throughout the lungs, it is crucial that you find and remove cancerous cells as soon as possible. (sharecare.com)
  • Ask your doctor how to stay healthy while being treated for bronchoalveolar carcinoma. (sharecare.com)
  • bronchioalveolar carcinoma ( bronchiolar carcinoma ) ( bronchioloalveolar carcinoma ) ( bronchoalveolar carcinoma ) a variant type of adenocarcinoma of the lung , with columnar to cuboidal epithelial cells lining the alveolar septa and projecting into alveolar spaces in branching papillary formations. (thefreedictionary.com)
  • An abdominal CT showed a well-defined lesion in the superior right hepatic lobe consistent with a hepatic cyst and a mildly enlarged and heterogeneous left hepatic lobe concerning for possible hepatocellular carcinoma. (hindawi.com)
  • cholangiocellular carcinoma a rare type of hepatocellular carcinoma arising from the cholangioles , consisting of two layers of cells surrounding a minute lumen. (thefreedictionary.com)
  • [1] [2] As a class, NSCLCs are relatively insensitive to chemotherapy , compared to small cell carcinoma. (wikipedia.org)
  • Because small cell and large cell neuroendocrine carcinomas of the gastrointestinal tract are usually found at an advanced stage, treatment often begins with a combination of platinum-based chemotherapy drugs. (mskcc.org)
  • Small-cell prostate carcinoma (SCPC) morphology predicts for a distinct clinical behavior, resistance to androgen ablation, and frequent but short responses to chemotherapy. (aacrjournals.org)
  • Thirteen months earlier, he developed small cell carcinoma of the lung and received 6 cycles of chemotherapy. (eurekamag.com)
  • Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. (harvard.edu)
  • Dear Editor, We read the paper by Chadha and Wright on small margin excision of periocular basal cell carcinoma (BCC) with interest. (bmj.com)
  • DLC-1 tumor supressor gene induces apoptosis in human non-small cell lung carcinoma cells following a unique process of cell morphological changes and protein nuclear translocation. (cdc.gov)
  • Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 '-deoxycytidine. (cdc.gov)
  • In the present study, we investigated the effect of trifluoperazine on (a) survival of bleomycin-treated human non-small cell lung carcinoma U1810 cells, (b) induction and repair of bleomycin-induced DNA strand breaks, and (c) nonhomologous end-joining (NHEJ), the major DNA double-strand break (DSB) repair pathway in mammalian cells. (diva-portal.org)
  • Atezolizumab was associated with a significant improvement in overall survival (HR for death = 0.70) Small-cell carcinoma of the lung usually presents in the central airways and infiltrates the submucosa leading to narrowing of bronchial airways. (wikipedia.org)
  • 10- and 20-year survival is 63% and 44% respectively (papillary thyroid carcinoma has 95% 10-year survival). (thefreedictionary.com)
  • in contrast, papillary thyroid carcinoma has 95% 5- and 10-yr survival. (thefreedictionary.com)
  • It has been hypothesized that chronic inflammation is a major consequence of certain environmental factors eventually leading to increased proliferation, survival, and migration of epithelial cells, as well as angiogenesis in the adjacent stroma, thereby promoting epithelial tumor development ( 4 - 6 ). (pubmedcentralcanada.ca)
  • INTRODUCTION: Little is known about small cell carcinoma of the upper urinary tract (UUT-SCC), the aim of this study is to identify the risk factors in relation to survival of patients with UUT-SCC. (minervamedica.it)
  • DOI=10.1073/pnas.81.2.568 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. (mskcc.org)
  • On average, the frequencies of micronuclei increased during the first half of therapy and declined thereafter, reaching, in some patients with ovarian carcinoma, values below the pre-treatment level. (ovid.com)
  • Squamous cell carcinomas (8.1%) and large cell carcinomas (12.1%) showed high PD-L1 expression more commonly than adenocarcinomas (5.1%) but this was not statistically significant (p=0.072). (garvan.org.au)
  • The patient was diagnosed with Bowen's disease and developed extensive-stage small-cell carcinoma of the lung 10 years and 47 years, respectively, after the onset of arsenic exposure. (thefreelibrary.com)
  • basosquamous carcinoma carcinoma that histologically exhibits both basal and squamous elements. (thefreedictionary.com)
  • Dustin Diamond has stage 4 small cell carcinoma, according to his rep. (yahoo.com)
  • Histologically, this type has sheets of highly atypical cells with focal necrosis, with no evidence of keratinization (as is typical of SCC) or gland formation (as is typical of adenocarcinomas). (medscape.com)
  • In 8% of cases (4/50) adenocarcinoma was histologically confirmed, in 10% (5/50) of the cases the squamous carcinoma was confirmed, and there was one case of urothelial carcinoma, one case of sarcoma and one undifferentiated carcinoma. (srce.hr)
  • 1)The authors justify the use of small margins, without margin control (excision and closure without confirmation of histologically clear margins) by their low recurrence rates over a follow up period ranging from 37-59 months. (bmj.com)
  • These pathways complement our catalog of research reagents for the study of Non-small Cell Lung Carcinoma including antibodies and ELISA kits against EGFR, TP53, VEGFA, MID1, CDKN2A. (novusbio.com)
  • No somatic mutations were detected in the mutation cluster regions of the KRAS, EGFR, BRAF and PIK3CA genes and the entire coding region of p53 in the carcinoma, and the expression of ALK fusion was negative. (spandidos-publications.com)
  • The lysates from indicated cell lines were subjected to immunoprecipitation with anti-EGFR antibody, followed by Western blot analysis for MET in the immune complexes. (aacrjournals.org)
  • C and D, inhibition by SGX523 and/or erlotinib of ligand-dependent and -independent activation of MET, EGFR, and their downstream signaling in MET-amplified cells. (aacrjournals.org)
  • Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. (selleckchem.com)
  • On August 31st2019, Ho Chi Minh City Oncology Hospital cooperated with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, to hold a Scientific Seminar About Diagnosing and Treating Non-Small-Cell Lung Carcinoma Having EGFR Mutation for doctors to discuss and share their experiences in treating the condition. (fvhospital.com)
  • Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach. (ecancer.org)
  • A small cell bronchogenic carcinoma associated with tumoral hypophosphataemia and inappropriate antidiuresis. (bmj.com)
  • bronchogenic carcinoma any of a large group of carcinomas of the lung, so called because they arise from the epithelium of the bronchial tree. (thefreedictionary.com)
  • large cell carcinoma a type of bronchogenic carcinoma of undifferentiated (anaplastic) cells of large size, a variety of squamous cell carcinoma that has undergone further dedifferentiation. (thefreedictionary.com)
  • Ursolic Acid and oleanolic acid reduced the proliferation of A549 cells in nude mice. (greenmedinfo.com)
  • In a small interfering RNA (siRNA)-based high-throughput wound healing screen performed in A549 lung carcinoma cells, we identified ERK2 but not ERK1 as a strong mediator of HGF-induced motility. (biologists.org)
  • This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through first line systemic therapy containing an immune checkpoint inhibitor (ICI). (clinicaltrials.gov)
  • however, it is not uncommon for these cells to arise in nonpulmonary sites, as extrapulmonary small cell carcinoma (EPSCC). (medscape.com)
  • [ 2 ] Since extrapulmonary small cell carcinoma has been reported in multiple sites, all cases are thought to have an identical cell of origin that derives from those originating in neural crest and then migrates to different epithelial sites within the body. (medscape.com)
  • Extrapulmonary small cell carcinoma has been reported to arise in almost all body sites except the central nervous system. (medscape.com)
  • [ 6 ] Global incidence of extrapulmonary small cell carcinoma is unknown. (medscape.com)
  • This article reviews the recent literature on extrapulmonary small cell carcinomas. (biomedsearch.com)
  • Merkel cell polyomavirus infection and Merkel cell carcinoma. (aad.org)
  • Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. (aad.org)
  • 2. renal cell carcinoma . (thefreedictionary.com)
  • Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC (2001) Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. (springer.com)
  • It is often misdiagnosed as transitional cell carcinoma, owing to the similarities in presentation. (urotoday.com)
  • In 1993, a skin biopsy of a lesion on his right elbow was positive for squamous cell carcinoma in situ. (thefreelibrary.com)
  • Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. (nih.gov)
  • adenocarcinoma of the lung , large cell carcinoma , small cell carcinoma , and squamous cell carcinoma . (thefreedictionary.com)
  • We compared the expression and genomic profiles of SCPC and large-cell neuroendocrine carcinoma (LCNEC) xenografts to those of typical prostate adenocarcinoma xenografts. (aacrjournals.org)
  • We previously characterized 8 SCPC and large-cell neuroendocrine (NE) carcinoma (LCNEC) xenograft tumor lines derived from tumor of a single patient ( 4 ). (aacrjournals.org)
  • See Anaplastic carcinoma of thyroid, Follicular tumor of thyroid, Papillary carcinoma of thyroid, Thyroid lymphoma. (thefreedictionary.com)
  • Gastrointestinal small cell carcinoma and large cell carcinoma are usually diagnosed at an advanced stage, after they have spread to the lymph nodes or other organs. (mskcc.org)
  • Gastrointestinal tract small cell carcinoma is an infrequent and aggressive neoplasm that represents 0.1-1% of gastrointestinal malignancies. (springer.com)
  • Gastrointestinal tract small cell carcinoma is an infrequent and aggressive malignancy. (springer.com)
  • Small cell carcinoma of the urinary bladder successfully managed with palliative radiotherapy and immunotherapy. (alliedacademies.org)
  • Cells were stimulated with nicotine and genes that were differentially expressed upon nicotine stimulation and ID1 depletion were analyzed to identify potential downstream targets of ID1. (springer.com)
  • This cell line was established from a lung metastasis from a person with lung small cell carcinoma. (mskcc.org)
  • High level of serum CRP,lower serum albumin,lower pleural protein,MPE with distant metastasis were determined to be the most important prognostic factors for non small cell lung carcinoma patients with MPE. (ersjournals.com)
  • Concomitant therapy with other anti-neoplastic agents or experimental agents except for small volume radiation to a solitary bony metastasis. (knowcancer.com)
  • Biopsy A small sample of the tumor may be obtained for examination under a microscope using either a thin needle (fine-needle aspiration biopsy) or a wider needle (core biopsy). (mskcc.org)
  • Bronchoscopy revealed a right middle-lobe tumor, and the biopsy was positive for small-cell lung carcinoma. (thefreelibrary.com)
  • Biopsy showed small cell esophageal carcinoma. (springer.com)
  • Biopsy was taken and its evaluation revealed tumor to be small cell carcinoma. (alliedacademies.org)
  • The antibodies bind to normal human cells to a much lesser degree than to tumor cells. (freepatentsonline.com)
  • HF exerts in vitro a reversible antiproliferative activity with a block observed in the G1 phase the cell cycle. (nih.gov)
  • Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A rare case after In Vitro Fertilization. (thefreelibrary.com)
  • A number of other malignancies, including those derived from the ovary, stomach, small bowel, and urothelium, have also been linked to this syndrome. (unboundmedicine.com)
  • Pathology obtained from transurethral resection of the prostate revealed pure small cell carcinoma of the prostate. (urotoday.com)
  • Modeling human prostate carcinoma with xenografts allows in-depth and detailed studies of its underlying biology. (aacrjournals.org)
  • Small-cell carcinoma morphology is often found on repeat biopsies during castrate-resistant prostate carcinoma (CRPC) progression ( 1-3 ). (aacrjournals.org)
  • Its presence predicts for a course characterized by frequent visceral metastases, predominantly lytic bone lesions, and large prostatic, or nodal masses, which is distinct from that of the typical bone-homing, hormone-responsive prostate carcinoma. (aacrjournals.org)
  • Small-cell prostate carcinomas (SCPC) do not express androgen receptor (AR) and thus do not respond to androgen ablation. (aacrjournals.org)
  • A few of the less common types are pleomorphic, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma. (wikipedia.org)
  • With improved histopathologic procedures and the use of electron microscopy, most NSCLCs that would previously have been classified as large-cell carcinomas are identified as undifferentiated adenocarcinomas or, less frequently, as SCCs. (medscape.com)
  • Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours. (urotoday.com)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • Compared to non-small cell carcinoma, small cell carcinoma has a shorter doubling time, higher growth fraction, and earlier development of metastases. (wikipedia.org)
  • A monoclonal antibody (mAb L6) to a small-cell lung carcinoma surface antigen recognizes a common epitope of vasopressin-neurophysin and oxytocin-neurophysin in hypothalamic nuclei. (pnas.org)
  • Immunohistochemical detection was performed for cytokeratin, epithelial membrane antigen, neuron-specific enolase (NSE), synaptophysin (Syn), chromogranin A (CgA), neuronal cell adhesion molecules (CD56), thyroid transcriptional factor-1 and S100 protein (S100). (ovid.com)
  • Transient EZH2 inhibition expands these non-neuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. (aacrjournals.org)
  • [ 1 ] Small cell carcinoma is a distinct clinical and pathologic entity that arises from cells of the amine precursor uptake and decarboxylation (APUD) system. (medscape.com)
  • The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical interest, since NSCLCs that express such fusion oncokinases are reportedly sensitive to kinase inhibitors. (spandidos-publications.com)
  • Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a very rare and lethal tumor, mostly affecting young women, with aggressive clinical course. (thefreelibrary.com)
  • Very few cases of small cell esophageal carcinoma arising in Barrett's esophagus have been reported in the literature. (springer.com)
  • Although small cell esophageal carcinoma is rare and its association with dysplastic Barrett's esophagus is extremely infrequent, the high carcinogenic risk of Barrett's epithelium should be kept in mind. (springer.com)